S-nitroso-L-cysteine stereoselectively blunts the adverse effects of morphine on breathing and arterial blood gas chemistry while promoting analgesia

Paulina M. Getsy\textsuperscript{a}, Alex P. Young\textsuperscript{b}, James N. Bates\textsuperscript{c}, Santhosh M. Baby\textsuperscript{d,1}, James M. Seckler\textsuperscript{e}, Alan Grossfield\textsuperscript{f}, Yee-Hsee Hsieh\textsuperscript{g}, Tristan H.J. Lewis\textsuperscript{a}, Michael W. Jenkins\textsuperscript{a,e}, Benjamin Gaston\textsuperscript{h}, Stephen J. Lewis\textsuperscript{a,i,j,*}

\textsuperscript{a}Department of Pediatrics, Case Western Reserve University, Cleveland, OH, USA
\textsuperscript{b}Department of Pediatrics, University of Virginia, Charlottesville, VA, USA
\textsuperscript{c}Department of Anesthesia, University of Iowa, Iowa City, IA, USA
\textsuperscript{d}Galleon Pharmaceuticals, Inc., 213 Witmer Road, Horsham, PA, USA
\textsuperscript{e}Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, USA
\textsuperscript{f}Department of Biochemistry and Biophysics, University of Rochester Medical Center, Rochester, NY 14642, USA
\textsuperscript{g}Division of Pulmonary, Critical Care and Sleep Medicine, Case Western Reserve University, Cleveland, OH, USA
\textsuperscript{h}Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Correspondence to: Stephen J. Lewis, PhD. Department of Pediatrics, Division of Pulmonology, Allergy and Immunology, Department of Pharmacology School of Medicine, Biomedical Research Building, Room 839A, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4984, USA. santhosh.m.baby@galvani.bio (S.M. Baby), sjl78@case.edu (S.J. Lewis).

Current address: Translational Sciences Treatment Discovery, Galvani Bioelectronics, Inc., 1250 S Collegeville Rd., Collegeville, PA 19426, USA.

CRediT authorship contribution statement

Paulina M. Getsy: Conceptualization, Writing – original draft, Writing – review & editing. Alex P. Young: Conceptualization, Investigation, Writing – review & editing. James N. Bates: Conceptualization, Writing – original draft, Writing – review & editing. Santhosh M. Baby: Conceptualization, Investigation, Writing – review & editing. James M. Seckler: Conceptualization, Writing – original draft, Writing – review & editing. Alan Grossfield: Conceptualization, Writing – review & editing. Yee-Hsee Hsieh: Conceptualization, Writing – review & editing. Tristan H.J. Lewis: Investigation, Writing – review & editing. Michael W. Jenkins: Conceptualization, Writing – original draft, Writing – review & editing. Benjamin Gaston: Conceptualization, Writing – original draft, Writing – review & editing. Stephen J. Lewis: Conceptualization, Investigation, Writing – original draft, Writing – review & editing.

Ethics Statement

The Institutional Animal Care And Use Committees (IACUC) of the University Of Virginia (Charlottesville, VA), Case Western Reserve University (Cleveland, OH), and Galvani Pharmaceuticals, Inc. (Horsham, PA) provided official approval for the studies presented in this manuscript.

Declaration of conflicting interests

The authors declare that they have no competing financial interests or personal relationships that would have influenced the studies that are described in this manuscript.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.biopharma.2022.113436.
Abstract

S-nitrosothiols exert multiple effects on neural processes in the central and peripheral nervous system. This study shows that intravenous infusion of S-nitroso-L-cysteine (SNO-L-CYS, 1 μmol/kg/min) in anesthetized male Sprague Dawley rats elicits (a) sustained increases in minute ventilation, via increases in frequency of breathing and tidal volume, (b) a decrease in Alveolar-arterial (A-a) gradient, thus improving alveolar gas-exchange, (c) concomitant changes in arterial blood-gas chemistry, such as an increase in pO$_2$ and a decrease in pCO$_2$, (d) a decrease in mean arterial blood pressure (MAP), and (e) an increase in tail-flick (TF) latency (antinociception). Infusion of S-nitroso-D-cysteine (SNO-D-CYS, 1 μmol/kg/min, IV), did not elicit similar responses, except for a sustained decrease in MAP equivalent to that elicited by SNO-L-CYS. A bolus injection of morphine (2 mg/kg, IV) in rats receiving an infusion of vehicle elicited (a) sustained decreases in frequency of breathing tidal volume, and therefore minute ventilation, (b) a sustained decrease in MAP, (c) sustained decreases in pH, pO$_2$ and maximal sO$_2$ with sustained increases in pCO$_2$ and A-a gradient, and (d) a sustained increase in TF latency. In rats receiving SNO-L-CYS infusion, morphine elicited markedly smaller changes in minute ventilation, arterial blood gas chemistry, A-a gradient and MAP. In contrast, the antinociceptive effects of morphine were enhanced in rats receiving the infusion of SNO-L-CYS. The morphine-induced responses in rats receiving SNO-D-CYS infusion were similar to vehicle-infused rats. These data are the first to demonstrate that infusion of an S-nitrosothiol, such as SNO-L-CYS, can stereoselectively ameliorate the adverse effects of morphine on breathing and alveolar gas exchange while promoting antinociception.

Keywords
S-nitrosothiol; Morphine; Respiratory depression; Antinociception; Sprague Dawley rats

1. Introduction

S-nitrosothiols are endogenous compounds that affect neural processes within the central [1–8] and peripheral [9–14] nervous systems. Extracellular and intracellular S-nitrosothiols affect neural activity via multiple mechanisms, including (a) their decomposition to nitric oxide (NO) and formation of di-nitrosothiol-iron complexes and subsequent activation of soluble guanylate cyclase/protein kinase G (PKG)-dependent processes [15–21], and (b) by transferring NO$^+$ moieties (i.e., S-nitrosylation) to thiol residues of numerous functional proteins, such as N-methyl-D-aspartate (NMDA) glutamatergic receptors [18,22–31]. Some endogenous S-nitrosothiols, including S-nitroso-L-cysteine (SNO-L-CYS), also exert their effects by direct activation of stereoselective recognition sites (i.e., sites that are minimally activated by SNO-D-CYS), such as sites present on voltage-gated K$^+$-channels, in a process that does not require S-nitrosylation of the functional protein [14]. Microinjections of SNO-L-CYS into the nucleus tractus solitarius (NTS) increase minute ventilation (V$_E$) in freely-moving rats [32] and decrease mean arterial blood pressure in anesthetized rats.
[33] by stereospecific mechanisms independent of decomposition to nitric oxide (NO). Similarly, microinjections of SNO-L-CYS, but not SNO-D-CYS, into the fourth ventricle [34] or lateral ventricles [35] elicit pronounced hemodynamic responses in freely-moving rats. In addition, it is evident that systemic injections of SNO-L-CYS dose-dependently increase V̇E by activation of stereoselective processes within the carotid bodies of freely-moving rats since these responses were not elicited by SNO-D-CYS and because the SNO-L-CYS responses were markedly diminished in rats with bilateral transection of the carotid sinus nerves [14]. Further studies in mice have also confirmed a role of endogenous S-nitrosothiols in the ventilatory responses that occur during and following hypoxic gas challenges [36,37]. Finally, systemic injections of S-nitrosothiols, such as SNO-L-CYS [38] and S-Nitroso-β,β-dimethyl-L-cysteine [39], exert dose-dependent vasodilation in freely-moving and anesthetized rats by processes independent of nitric oxide generation [14,40–43], but that are dependent upon stereoselective recognition sites, such as those present on ion-channels [14,22,44], whose functional status is regulated by oxidation-reduction reactions [45–49].

The role(s) of nitrosyl factors, such as nitric oxide and S-nitrosothiols, in the pharmacological actions of opioids has received much attention with potential roles for nitrosyl factors being identified in μ-opioid receptor (μ-OR) signaling [50–53], opioid tolerance [54–56], fentanyl pre-conditioning processes [57], opioid effects within the eye [58], opioid-induced catalepsy [59], opioid effects on vascular function [60,61], pain processing [62–67], and inflammatory-immunoregulatory processes [68,69]. There is very limited evidence as to the participation of nitrosyl factors in the ventilatory depressant effects of opioids. Teppema et al. [70], reported that the ventilatory depressant effects of morphine are independent of neuronal nitric oxide synthase (nNOS) in anesthetized cats. Pellegrino et al. [62], provided evidence that the ventilatory depressant responses elicited by fourth ventricular infusions of morphine in awake dogs were diminished by prior injection of the nitric oxide synthase (NOS) inhibitor, L-nitro-arginine (L-NA), whereas injection of L-NA following morphine was ineffective. In contrast, pre- or post-treatment with L-NA augmented the analgesic actions of morphine in these dogs [62]. In addition, recent studies from our laboratory [71], provided evidence that the ventilatory depressant effects of fentanyl, a popular synthetic opioid, were augmented in unanesthetized rats that had received the NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME). This finding by Seckler et al. [71], suggests that the major role of nitrosyl factors in the rat is to combat the inhibitory actions of opioids on breathing, although the sites and mechanisms responsible for the actions of nitrosyl factors remain to be determined. Current research has shown that S-nitrosothiols modulate G protein-coupled receptor signaling in a reversible and receptor-specific manner [72–74], although neither SNO-L-CYS or S-nitroso-L-glutathione appeared to directly interact with μ-ORs [74].

On the basis of the above findings, the objectives of this study were to (a) determine the ventilatory depressant effects and changes in blood pressure elicited by injection of morphine in isoflurane-anesthetized rats that were receiving a continuous infusion of (i) SNO-L-CYS, a ventilatory stimulant [14], (ii) L-cysteine, infused to determine the degree to which the S-nitrosothiol is the active compound, or (iii) SNO-D-CYS, infused to establish whether stereoselectivity is an important factor; and (b) determine
the antinociceptive actions of morphine in separate groups of unanesthetized male Sprague Dawley rats that were receiving the same protocol described in (i), (ii) and (iii). The primary finding was that the infusion of SNO-L-CYS, but not SNO-D-CYS, markedly blunted the depressant effects of morphine on frequency of breathing (f_R), tidal volume (V_T) and minute ventilation (V_E) while promoting morphine-induced antinociception. These data suggest that exogenously administered SNO-L-CYS modulates the pharmacological effects of morphine via modulation of the intracellular signaling pathways recruited by μ-ORs rather than by direct effects on μ-ORs.

2. Materials and methods

2.1. Permissions and rats

All animal studies were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication no. 80.23) revised in 1996. The protocols were approved by the Institutional Animal Care and Use Committees of the University of Virginia, Case Western Reserve University and Galleon Pharmaceuticals, Inc. Adult male Sprague Dawley rats were obtained from ENVIGO Laboratories (Indianapolis, IN). These rats were housed under standard conditions in the animal resource center (ARC) with free access to food and water. Room temperature (22 °C), humidity (48–50 %) and light-dark cycle (12:12 h) were maintained consistently in the ARC and laboratories where the studies took place.

2.2. Surgical procedures and protocols for cardiorespiratory studies

Adult male Sprague Dawley rats were anesthetized with 2.5 % isoflurane in a mixture of oxygen (O_2) and medical grade room-air (50 % O_2: 50 % room-air). Upon induction of surgical plane of anesthesia, evaluated by loss of the corneal blink reflex and hindlimb withdrawal, the rats were placed in the supine position on a thermostatically controlled blanket (Harvard Apparatus, MA, USA) connected to a rectal thermometer to keep body temperature at 37.4 ± 0.2 °C. The rats continued to breath 2.5 % isoflurane in medical grade room-air via a nose cone. A neck incision was made allowing for the vertical trachea to be cannulated with PE-90 tubing (Intramedic; Becton & Dickinson, Franklin Drive, NJ, USA). The tubing was then connected to a pneumotachometer flow head (MLT1L, AD Instruments, CO) to continuously measure respiratory flow [75]. The respiratory flow waveforms were used to determine f_R from the cycle period, and were integrated to calculate V_T. V_E was calculated by multiplying f_R by V_T. The femoral artery was cannulated with a PE-50 catheter (Intramedic; Becton & Dickinson, Franklin Drive, NJ, USA). This tubing was connected to a fluid-filled piezo-resistive pressure transducer (SP844, ADInstruments, Inc. Bella Vista, Australia) to permit the continuous monitoring of arterial blood pressure, and withdrawal of arterial blood samples (100 μL each). Another catheter (PE-50 connected to PE-10, the latter inserted into the vessel) was placed in the ipsilateral femoral vein to give a bolus injection of morphine (2 mg/kg, IV) or vehicle (saline, 100 μL/100 g, IV). A third catheter (PE-50 connected to PE-10, the latter inserted into the vein) was inserted into the right jugular vein and then connected to an infusion pump (Standard Infuse-Withdraw Pump 11 Pico Plus Elite Programmable Syringe Pump; Harvard Apparatus, MA, USA) to allow
for the continuous infusion of vehicle (20 μL/min, IV), SNO-L-CYS (1 μmol/kg/min, IV), L-cysteine (1 μmol/kg/min, IV) or SNO-D-CYS (1 μmol/kg/min, IV).

2.3. Arterial blood gas chemistry and alveolar-arterial (A-a) gradient

At pre-determined times during the experiment, arterial blood samples were taken to determine pH, pCO$_2$, pO$_2$ and maximal sO$_2$ as described in detail previously [76–78]. To collect arterial blood samples, any residual saline between the rat and the tubing connecting the syringe was removed and 125 μL of arterial blood was collected with a pre-heparinized 1 ml syringe. The syringe was capped and gently rotated for 10 s to mix the heparin (Hann’s Pharma, Wilmington, DE) and blood to prevent clotting. The sample was immediately injected into the blood gas analyzer (ABL 800 Flex; Radiometer, Westlake, OH) to determine pH, pCO$_2$, pO$_2$ and maximal sO$_2$. The Alveolar-arterial (A-a) gradient (i.e., the established index of alveolar gas exchange) was determined as detailed previously [76–78]. In brief, the A-a gradient was determined by the equation, PAO$_2$–PaO$_2$, where PAO$_2$ is the partial pressure of alveolar O$_2$ and PaO$_2$ is pO$_2$ in arterial blood. PAO$_2$ = [FiO$_2$ × (P$_{atm}$ − P$_{H2O}$) − (PaCO$_2$/respiratory quotient)], where FiO$_2$ is the fraction of O$_2$ in inspired air; P$_{atm}$ is atmospheric pressure; P$_{H2O}$ is the partial pressure of water in inspired air; PaCO$_2$ is pCO$_2$ in arterial blood; and respiratory quotient (RQ) is the ratio of CO$_2$ eliminated/O$_2$ consumed. We took FiO$_2$ of room-air to be 21 % = 0.21, P$_{atm}$ to be 760 mmHg, P$_{H2O}$ to be 47 mmHg and took the RQ value of our adult male Sprague Dawley rats to be 0.9 [76–78].

2.4. Antinociception surgeries and protocol

The antinociception assays were performed in adult male Sprague Dawley rats that had received two catheter implants under 2.5 % isoflurane anesthesia 7 days previously. This was done in order to test rats that were as free from surgical discomfort as possible. The catheters were exteriorized to the back of the neck and all wounds were closed as described previously [35,38–40]. One catheter (PE-50 connected to PE-10, the latter inserted into the right jugular vein) allowed for continuous infusion of vehicle (20 μL/min, IV), SNO-L-CYS (1 μmol/kg/min, IV), L-cysteine (1 μmol/kg/min, IV) or SNO-D-CYS (1 μmol/kg/min, IV). The other catheter (PE-50 connected to PE-10, the latter inserted into the left jugular vein) was for the injection of morphine (2 mg/kg, IV). On the day of the experiment, antinociception was determined by the radiant heat tail-flick (TF) assay as detailed previously [76–79]. In brief, prior to administration of morphine, the rats were allowed to freely crawl inside a canvas garden glove and were then lightly restrained in the glove to allow for the thermal withdrawal latencies to be determined. After administration of morphine, placement of the rat within the glove was done by the investigator. The TF testing apparatus consisted of a beam of focused radiant heat provided by a 50 W projector lamp, which was focused on the underside of the tail at 1 of 5 sites 8–10 mm apart. TF latency was measured to the nearest 0.1 s as the time from onset of heating of the tail to withdrawal of the tail from the heat. The intensity of the light beam was set so that the baseline TF latencies were about 2.5 s. A cutoff time of 12 s was set to minimize potential damage to the tail upon repeated application of the radiant heat beam. TF latencies were established before and during the various stages of the experiment. The data are shown as actual TF...
latencies (sec) and as “maximum possible effect” (%MPE) using the formula, 
\[
%\text{MPE} = \left(\frac{\text{post-injection TF latency} - \text{baseline TF latency}}{12 - \text{baseline TF latency}}\right) \times 100.
\]

2.5. Drugs and preparation of S-nitrosothiol infusions

Saline (vehicle) and morphine sulfate solution (50 mg/ml) were purchased from Hospira Inc. (Lake Forest, IL, USA). Working dilutions of morphine (10 mg/ml) was prepared in saline. L-Cysteine hydrochloride and D-cysteine hydrochloride were from Sigma Chemical (St. Louis, MO). Stock solutions of SNO-L-CYS and SNO-D-CYS were prepared just before use, as described previously [14,35,38], by reacting 1 ml solutions of (a) 50 mM sodium nitrite (containing 100 μL of 1 N HCl) and (b) 50 mM of L- or D-cysteine, which resulted in a stable 25 mM stock solution of approximately pH = 3 of the respective isomers. The solutions were diluted in alkalinized saline to increase the pH of the SNO-L-CYS or SNO-D-CYS solutions to approximately pH = 6.8. The SNO-L-CYS and SNO-D-CYS solutions were infused at 1 μmol/kg/min, with an infusion rate of 20 μL/min. For example, infusion of a 10 mM solution (10 nmol/μL) at 20 μL/min to a 200 g rat would result in the infusion of (10 nmol × 20 μL)/0.2 kg = 1000 nmol/kg/min = 1 μmol/kg/min. The stock and test solutions of SNO-L-CYS and SNO-D-CYS were routinely examined spectrophotometrically [14,35,38,80] to ensure that the concentrations of the stereoisomers were identical.

2.6. Data analyses

All data are presented as mean ± SEM and were evaluated using t-test (simple comparison between two means) or by one-way ANOVA (simple comparisons between three means) and two-way ANOVA (repeated measures analyses comparing between group values at the stated time points) followed by Bonferroni corrections for multiple comparisons between means using the error mean square terms from each ANOVA analysis [81–83] as detailed previously [84]. A value of P < 0.05 was taken as the initial level of statistical significance for the multiple comparisons testing [81–83]. The statistical analyses were performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). In accordance with the need for greater transparency of statistical findings [85], we have presented the results of the tests and initial ANOVA analyses underneath each Figure and Table. We present two F-statistics for the repeated measures ANOVA analyses. The first F-statistic presented for the repeated measures ANOVA analyses pertains to between group comparisons. For example, for 3 groups of rats, with 9 rats per group, the F-statistic, F(number of groups - 1, number of rats - 1 for each), would be denoted as $F_{2,24}$. The second F-statistic presented for the repeated measure ANOVA pertains to the interaction over the number of sample times. For instance, 7 repeated measures/timepoints with the F-value designated as sum of n-1 for the 3 groups of 9 rats each $= 8 + 8 + 8 = 24$, and n-1 rats x n-1 times of observation $= 8 \times 6 + 8 \times 6 + 8 \times 6 = 144$, thus the F-statistic would be denoted as $F_{24,144}$.

3. Results

3.1. Body weights and baseline values for the treatment groups

The body weights and baseline values for each of the recorded parameters are summarized in Supplemental Tables 1–3. There were no significant between group differences for any body weight or parameter values in these studies (P > 0.05, for all comparisons). The
3.2. Ventilatory parameters

As seen in Fig. 1, the continuous infusion of vehicle did not alter $f_R$, $V_T$, $V_E$ or MAP, whereas the infusion of SNO-L-CYS (1 μmol/kg/min, IV) elicited sustained increases in $f_R$, $V_T$, and therefore $V_E$ that were accompanied by a sustained decrease in MAP. Although the infusion of SNO-D-CYS (1 μmol/kg/min, IV) did not affect $f_R$, $V_T$ or $V_E$, it did elicit a sustained decrease in MAP. The bolus injection of morphine (2 mg/kg, IV) given 25 min after commencing vehicle infusion (I25) elicited sustained decreases in $f_R$, $V_T$, $V_E$ and MAP in vehicle-treated rats. In rats receiving SNO-L-CYS, the injection of morphine elicited smaller decreases in $f_R$, $V_T$ and $V_E$ than in vehicle-infused rats, whereas MAP substantially increased over time. The injection of morphine (2 mg/kg, IV) elicited sustained decreases in $f_R$, $V_T$ and $V_E$ in SNO-D-CYS-infused rats that were of similar magnitude to vehicle-infused rats, and no change in MAP. The repeated measures ANOVA analyses showed significant interactions between treatments and time for $f_R$ ($F_{24,144} = 10.21, P < 0.0001$), $V_T$ ($F_{24,144} = 10.62, P < 0.0001$), $V_E$ ($F_{24,144} = 13.40, P < 0.0001$) and MAP ($F_{24,144} = 6.70, P < 0.0001$). The arithmetic changes in $f_R$, $V_T$, $V_E$ and MAP elicited by morphine in the rats that received the infusions of vehicle, SNO-L-CYS or SNO-D-CYS, are summarized in Fig. 2. The arithmetic changes in $f_R$, $V_T$, $V_E$ and MAP were clearly different between the SNO-L-CYS group of rats and their respective vehicle (control) group, whereas the arithmetic responses in the SNO-D-CYS and their respective vehicle (control) group were similar to one another. As such, the arithmetic responses in the SNO-L-CYS group were significantly different from those in the SNO-D-CYS group. The repeated measures ANOVA analyses showed significant interactions between treatments and time for $f_R$ ($F_{24,144} = 5.66, P < 0.0001$), $V_T$ ($F_{24,144} = 10.75, P < 0.0001$), $V_E$ ($F_{24,144} = 5.55, P < 0.0001$), and MAP ($F_{24,144} = 7.24, P < 0.0001$).

3.3. Arterial blood-gas chemistry and A-a gradient

As seen in Fig. 3, the infusion of vehicle or L-cysteine (1 μmol/kg/min, IV) did not alter pH, pCO$_2$, pO$_2$, maximal sO$_2$ or A-a gradient, whereas the infusion of SNO-L-CYS (1 μmol/kg/min, IV) elicited sustained increases in pO$_2$ accompanied by sustained decreases in pCO$_2$ and A-a gradient. The bolus injection of morphine (2 mg/kg, IV) given 25 min after commencing vehicle infusion (I25) elicited sustained decreases in pH, pO$_2$ and maximal sO$_2$ that were accompanied by sustained increases in pCO$_2$ and A-a gradient. In rats receiving the infusion of SNO-L-CYS, the injection of morphine elicited smaller decreases in pH, pO$_2$ and maximal sO$_2$ compared to vehicle-treated rats, and smaller increases in pCO$_2$ and A-a gradient than in vehicle-treated rats. The injection of morphine (2 mg/kg, IV) elicited sustained decreases in pH, pO$_2$ and maximal sO$_2$ along with sustained increases in pCO$_2$ and A-a gradient in L-cysteine-infused rats that were of similar magnitude in the vehicle-infused rats. The repeated measures ANOVA analyses showed significant interactions between treatments and time for pH ($F_{12,84} = 4.95, P < 0.0001$), pCO$_2$ ($F_{12,72} = 5.07, P < 0.0001$), pO$_2$, ($F_{12,72} = 5.74, P < 0.0001$), Maximal sO$_2$ ($F_{12,72} = 8.82, P < 0.0001$) and A-a gradient ($F_{12,72} = 5.67, P < 0.0001$). As seen in Fig. 4, the infusion of vehicle or SNO-D-CYS (1 μmol/kg/min, IV) did not alter pH, pCO$_2$, pO$_2$, maximal
sO₂ or A-a gradient. The bolus injection of morphine (2 mg/kg, IV) given 25 min after starting the infusions (I25) elicited sustained decreases in pH, pO₂ and maximal sO₂ that were accompanied by sustained increases in pCO₂ and A-a gradient. These morphine responses were similar in rats receiving infusion of vehicle or SNO-D-CYS. Repeated measures ANOVA analyses showed significant interactions between treatments and time for pH (F_{8,48} = 20.93, P < 0.0001), pCO₂ (F_{8,48} = 6.69, P < 0.0001), pO₂ (F_{8,48} = 10.08, P < 0.0001), maximal sO₂ (F_{8,48} = 6.92, P < 0.0001) and A-a gradient (F_{8,48} = 4.33, P = 0.0006). The arithmetic changes in pH, pCO₂, pO₂, maximal sO₂ or A-a gradient elicited by morphine in rats that received the infusions of vehicle, SNO-L-CYS or SNO-D-CYS are summarized in Fig. 5. Arithmetic changes in these parameters elicited by morphine were similar in the vehicle (control) groups for both SNO-L-CYS and SNO-D-CYS. In contrast, the arithmetic responses elicited by morphine were clearly blunted in rats that were receiving SNO-L-CYS infusion in comparison to their vehicle-infused counterparts, whereas the morphine responses were similar in the SNO-D-CYS rats compared to their respective vehicle controls. Accordingly, the arithmetic responses in the SNO-L-CYS group were different from those in the SNO-D-CYS group. The repeated measures ANOVA analyses showed significant interactions between treatments and time for pH (F_{20,100} = 9.88, P < 0.0001), pCO₂ (F_{20,100} = 8.05, P < 0.0001) pO₂ (F_{20,100} = 4.33, P < 0.0001), maximal sO₂ (F_{20,100} = 6.99, P < 0.0001) and A-a gradient (F_{20,100} = 4.84, P < 0.0001).

### 3.4. Antinociception

As shown in Fig. 6, the infusion (1 μmol/kg/min, IV) of SNO-L-CYS, but not SNO-D-CYS, elicited a minor, however sustained increase in tail-flick (TF) latency. The subsequent injection of morphine (2 mg/kg, IV) elicited pronounced and sustained increases in TF latency of rats receiving the infusions of vehicle for both the SNO-L-CYS and SNO-D-CYS groups. The morphine-induced increases in TF latency were more pronounced in the rats that were receiving the infusion of SNO-L-CYS, whereas the morphine-induced responses in the rats receiving SNO-D-CYS were equivalent to their vehicle (control) group. The repeated measures ANOVA analyses showed significant interactions between treatments and time for the SNO-L-CYS study (Panel A, F_{21,126} = 2.03, P = 0.0088) and SNO-D-CYS study (Panel B, F_{16, 96} = 3.105, P = 0.0003). Repeated measures ANOVA statistics for arithmetic changes in TF latencies (including the L-Cysteine group not shown in panels) shown in Panel C also showed significant interactions between treatments and time (F_{37,185} = 3.27, P < 0.0001). These findings expressed as a percentage of maximum possible effect (%MPE) are summarized in Supplemental Table 4. Morphine-induced increases in TF latency were greater in rats receiving infusion of SNO-L-CYS, whereas the antinociceptive effects of morphine were not altered in rats that were receiving infusions (1 μmol/kg/min, IV) of L-cysteine or SNO-D-CYS. The repeated measures ANOVA analyses showed significant interactions between treatments and time for the SNO-L-CYS study (F_{21,105} = 2.37, P = 0.0022) and the SNO-D-CYS study (F_{16,80} = 4.14, P < 0.0001).

### 4. Discussion

In this study SNO-L-CYS blunts the adverse effects of morphine on breathing without reducing the analgesic effects of the opioid. SNO-L-CYS is produced primarily by
metalloproteins, such as nitric oxide synthase (NOS), ceruloplasmin and hemoglobin [26,27,86,87–95]. It is well-known that S-nitrosothiols are important extracellular and intracellular signaling molecules [20,26,27]. For example, the hemoglobin R to T conformational switch caused by acidosis, hypercapnia, hypoxia and other physiological phenomena, stimulates the formation of signaling S-nitrosothiols, such as SNO-L-CYS [14,20,27,86–92]. Formation of S-nitrosothiols by NOS in endothelial cells and erythrocytes is important for blood pressure regulation, but not for regulation of peripheral blood flow. However, the opposite is true for SNO-L-CYS and other S-nitrosothiols formed during hemoglobin deoxygenation [89,93,95]. Recent evidence suggests that this class of low mass thiol-NO adducts is also stored in endothelial and neuronal vesicles for subsequent release [96]. Abnormal S-nitrosothiol levels have been measured ex vivo in a variety of human conditions, ranging from altitude acclimatization to diseases like asthma, pulmonary hypertension, and sepsis [89,90,97,98,99].

4.1. Effects of SNO-CYS and SNO-D-CYS on baseline parameters

The present study demonstrates that the continuous intravenous infusion(1 μmol/kg/min) of the endogenous S-nitrosothiol, SNO-L-CYS [80,96,100], elicits increases in fR, VT and VE in isoflurane-anesthetized rats. The lack of effects of the L-cysteine infusion suggests that the nitrosylation of the thiol residue in cysteine allows SNO-L-CYS activity that is not possessed by the parent thiol. The finding that SNO-D-CYS elicted minimal changes in ventilatory parameters supports current evidence that the ability of SNO-L-CYS to increase VE upon microinjection into the NTS [32] or upon systemic delivery to carotid bodies [14] involves stereoselective processes. These processes may include the ability of SNO-L-CYS, but not SNO-D-CYS, to undergo intracellular transport via an L-amino acid transporter system [101,102] to allow SNO-L-CYS to modulate the function/activities of intracellular signaling proteins [7,72,103–111]. These stereoselective processes may also include interaction with membrane-bound proteins, such as N-methyl-D-aspartate glutamatergic ligand-gated ion-channel receptors [44], T-type Ca\textsuperscript{2+}-channels [22], and voltage-gated K\textsuperscript{+}-channel sub-type 1.1 (K\textsubscript{v1.1}-channels) [14]. Additionally, Ca\textsuperscript{2+}-activated K\textsuperscript{+}-channels [18,23,105,112,113] and K\textsubscript{v1.2}− and K\textsubscript{v1.3}-channels [114], although stereoselectivity of the effect has not been confirmed for these channels.

The present study also shows that the continuous infusions of SNO-L-CYS and SNO-D-CYS at 1 μmol/kg/min) elicited equivalent and substantial reductions in MAP in the isoflurane-anesthetized rats. We have reported that bolus intravenous injections of S-nitrosothiols, such as SNO-L-CYS [38] and S-nitroso-β,β-dimethyl-L-cysteine [39], exert dose-dependent reductions in MAP due to reductions in regional vascular resistances in freely-moving and anesthetized rats [14,38–41]. The potencies of the respective D-isomers at lower doses (e.g., 10–200 nmol/kg, IV) are much smaller than that of the L-isomers in freely-moving rats, but the differences in potency diminish when higher doses (e.g., 400–800 nmol/kg, IV) of L- and D-isomers are given [38,39]. Moreover, the difference in potency of L- and D-isomers is smaller at all doses in anesthetized rats compared to freely-moving rats [39]. Thus, the similar reductions in MAP elicited by the infusion of SNO-L-CYS and SNO-D-CYS in the anesthetized rats is consistent with evidence that although infusion of SNO-L-CYS into the femoral artery of anesthetized sheep to elicit
blood concentrations of approximately 0.6 μmol/L induced a pronounced vasodilation in the ipsilateral hindlimb, infusion of these concentrations of SNO-D-CYS did not. Nonetheless, both infusions caused pronounced decreases in MAP upon reaching the general circulation. At present, the processes by which anesthetics alter the relative potencies of the L- and D-isomers remain to be determined [39]. Previous data suggest the equivalent decreases in MAP elicited by the infusions of SNO-L-CYS and SNO-D-CYS may involve the trans-nitrosylation of circulating proteins, such as albumin [115], to form the vasodilator, S-nitroso-albumin [116,117]. The infusion of SNO-L-CYS increased TF latency in freely-moving rats, whereas similar infusions L-cysteine or SNO-D-CYS did not. The rats showed no overt behavioral responses to the infusion of the SNO-L-CYS. In other words, there were instances of grooming events and movement during the infusion period and these events were not obviously different in frequency to the pre-infusion period or to those of the other infusion groups (e.g., L-cysteine and SNO-D-CYS). As such it is tempting to assume that the increase in TF latency was an actual antinociception effect by mechanisms and sites of action that we have not established at present. However, it has been established that SNO-L-CYS exerts pronounced antinociception by stereoselective effects via L-amino acid transport mechanisms in rat spinal cord [118–120], and potentially by stereoselective inhibition of CaV3.2 T-type Ca2+-channels within the thalamus and dorsal root ganglia [12,22].

4.2. Effects of SNO-L-CYS on morphine-induced responses

Key findings of this study were that the depressant effects of morphine on ventilatory parameters, ABG chemistry and A-a gradient were substantially diminished in Sprague Dawley rats that were receiving a continuous infusion of SNO-L-CYS, whereas the antinociceptive effects of the morphine were augmented during the infusion of SNO-L-CYS. The finding that morphine decreased MAP in vehicle-infused rats, whereas it reversed the hypotension elicited by SNO-L-CYS infusion, but not SNO-D-CYS infusion, also speaks to a complicated, but important interaction, between the signaling mechanisms elicited by SNO-L-CYS and morphine. Although far from definitive, these findings are consistent with evidence that S-nitrosothiols do not directly interact with μ-ORs [74], and suggest that SNO-L-CYS modulates the mechanisms and signaling pathways that are proposed to mediate the pharmacological actions of morphine [77,121–123]. The precise mechanisms by which SNO-L-CYS exerts these effects have yet to be established, however, the lack of efficacy of L-cysteine and SNO-D-CYS certainly suggests that stereoselective mechanisms, including intracellular uptake via an L-amino acid transporter system [101,102], thereby allowing SNO-L-CYS to modulate numerous intracellular signaling cascades involved in the cardiorespiratory system [72,103–111], are involved. We have reported that the NADPH diaphorase histochemical technique identifies the presence of S-nitrosylated proteins in central and peripheral tissues [96]. Evidence that acute administration of morphine elicits a marked decrease in NADPH diaphorase staining within the brain [124–126], raises the intriguing possibility that morphine promotes the use and/or de-nitrosylation of S-nitrosylated species within the brain, and possibly the peripheral structures that are normally rich in NADPH diaphorase staining, including the carotid bodies [127]. Moreover, prevention of the potential depletion of endogenous S-nitrosylated proteins (e.g., L-SNO-proteins) by the infusion of SNO-L-CYS may play a key role in (i) diminishing the adverse
cardiorespiratory actions of morphine (i.e., those on ventilatory parameters, ABG chemistry and A-a gradient) while (ii) enhancing the antinociceptive actions of the opioid.

### 4.3. Effects of SNO-L-CYS on morphine-induced changes in ventilatory parameters

In agreement with an earlier study in isoflurane-anesthetized rats [128], the bolus intravenous injection of a 2 mg/kg dose of morphine elicited sustained decreases in arterial blood pH, pO$_2$ and sO$_2$ that were accompanied by an increase in pCO$_2$, with all responses being indicative of hypoventilation, and pronounced increases in Alveolar-arterial gradient, which is indicative of ventilation-perfusion mismatch in alveoli. These responses closely align with a general understanding of the pharmacological effects of morphine in rats and humans, including those under anesthesia [128–131]. The ability of morphine to depress the ventilatory responses to hypoxic [132–134] and hypercapnic [134] gas challenges in humans, suggests that morphine and/or its metabolites [135] may depress central and peripheral (e.g., the carotid body) mechanisms that respond to these challenges [133,134]. It is established that morphine blunts ventilatory responses to hypoxic or hypercapnic gas challenges in rats [136–139]. Morphine probably blunts these ventilatory responses by actions in the central nervous system because (i) μ-ORs are expressed in nuclei involved in ventilatory control processes [140], (ii) microinjections of the μ-OR agonist, DAMGO, into the commissural NTS suppresses the ventilatory responses to hypoxic or hypercapnic gas challenges [140–142], and (iii) microinjections of DAMGO into the medullary raphe region of rats attenuate responses to hypoxic gas challenge. The probability that morphine suppresses ventilatory responses to hypoxic or hypercapnic challenges via peripheral actions was addressed by McQueen and Ribeiro [143] in anesthetized cats by examining the effects of intra-carotid administration of morphine or the δ-OR agonist, methionine-enkephalin, on chemoreceptor fiber activity in the carotid sinus nerve (CSN). Unexpectedly, they found that (i) morphine was minimally inhibitory at higher doses, while lower doses increased CSN discharge, and (ii) methionine-enkephalin elicited profound inhibition of CSN discharge [143]. In addition, CSN firing discharge evoked by intra-carotid injections of CO$_2$-saturated buffer solutions were augmented by morphine, whereas they were reduced by methionine-enkephalin [143]. In a later study, Kirby and McQueen [144] found that opioid depression of chemosensory discharge in cats involved δ-ORs rather than μ-ORs. It should also be noted that Zimpfer et al. [145] reported that morphine markedly attenuated the cardiovascular responses due to chemoafferent stimulation in conscious dogs. Whether this effect of morphine was due to actions in the brain and/or carotid bodies was not established.

Surprisingly, the possibility that morphine affects carotid body and CSN discharge or the responses of these structures to hypoxic and/or hypercapnic challenges, have not been examined directly in rats. We examined this possibility indirectly by determining the adverse effects of morphine (10 mg/kg, IV) on ventilatory responses elicited by hypoxic or hypercapnic challenges in freely-moving Sprague Dawley rats with prior (7 day) sham-operation or those with bilateral CSN transection, which disrupts chemosensory afferent input to the NTS [146]. We found that the ability of morphine to suppress ventilatory responses to hypoxic or hypercapnic challenges were actually exacerbated in CSN transected rats, providing the first in vivo evidence that carotid body chemoreceptors defend against, rather than participate in, the ability of morphine to depress breathing in
rats. These findings align with those of McQueen and Ribeiro [143], and suggest that the ability of SNO-L-CYS infusion to prevent morphine-induced suppression of breathing somehow involves the actions of this S-nitrosothiol within the carotid bodies. Recently, evidence has shown that SNO-L-CYS drives breathing via actions within the carotid bodies, and thus it is apparent that the L-isomer can affect signaling processes within the carotid body chemosensitive glomus cells and/or chemoafferent nerve terminals [14]. As such, the infusion of SNO-L-CYS may in some way allow morphine-induced stimulation of μ-ORs to promote glomus cell and/or chemoafferent activity thereby counteracting the adverse effects of morphine on breathing via other mechanisms (see below). Low doses of morphine (e.g., 1 mg/kg, IV) increase ventilation in adult [147] and fetal [148,149] rats. In adult rats, excitatory ventilatory responses elicited by morphine include increases in (i) fR (accompanied by decreases in inspiratory time and end inspiratory pause), (ii) VE, (iii) inspiratory drive, and (iv) peak inspiratory and expiratory flows [147]. Evidence has shown that the ability of the low dose of morphine to drive breathing involved activation of central μ- and/or δ-ORs, and that the ability of morphine to depress breathing by activation of peripheral μ- and/or δ-ORs masks the central actions. This evidence complements that of Szeto et al. [148], who found that morphine-induced stimulation of fetal breathing involved stimulation of μ1-ORs and activation of central muscarinic pathways. Whether infusion of SNO-L-CYS enhances the activity of the above mentioned central systems is not known, but it is known that central administration of SNO-L-CYS elicits an array of cardiorespiratory responses [32–35].

### 4.4. Effects of SNO-L-CYS on morphine-induced changes in A-a gradient

The precise mechanisms by which morphine increases A-a gradient, which compromises gas-exchange in lung alveoli, in naïve or isoflurane-anesthetized rats are unknown and a comprehensive search of the literature found no relevant publications. On the basis of numerous studies in humans, the two leading mechanisms by which morphine and isoflurane could increases A-a gradient would be via (i) atelectasis, which is collapse of alveoli via changes in intra-pleural pressures due to hypoventilation and/or changes in the effective concentration of surfactants responsible for maintaining alveolar integrity, and (ii) impaired clearance of fluids from the alveoli rather than by changes in pulmonary artery or pulmonary wedge pressures [150–152]. Indeed, isoflurane [153] and opioids, such as morphine [154–156] and fentanyl/fentanyl analogs [157,158], cause/promote atelectasis in humans, whereas there is little information as to whether opioids adversely affect fluid clearance from alveoli [159,160]. Although there is a lack of evidence with opioids, there is direct evidence that isoflurane decreases alveolar epithelial fluid clearance in rats [161] although the A-a gradients recorded in our isoflurane-anesthetized rats of the present study were very similar to those recorded in freely-moving unanesthetized rats [76–78]. It is possible that the interaction of isoflurane and morphine leads to a more dramatic effect of morphine on intracellular processes that underlie the increases in A-a gradient elicited by the opioid. Whether the mechanisms by which morphine inhibits gas transfer within the lungs involve atelectasis, diminished fluid clearance in alveoli, or other potential mechanisms [150–152], an obvious question relates to how SNO-L-CYS can markedly diminish the increase in A-a gradient elicited by morphine. The decomposition of SNO-L-CYS is unlikely to be involved since nitric oxide inhibits alveolar fluid clearance [162], lung sodium transport
through alveolar type 1 and 2 cells [163, 164], and amiloride-sensitive Na⁺ transport [165] via soluble guanylate cyclase/cGMP-dependent processes. As such, SNO-L-CYS may prevent the adverse effects of morphine on A-a gradient by direct activation of ion-channels and/or by S-nitrosylation of functional proteins [14] relevant to the inhibitory effects of morphine. To date there is no available data regarding whether, for example, SNO-L-CYS is able to directly bind to or indirectly modulate, via S-nitrosylation, the amiloride amiloride-sensitive Na⁺ transport system. We are currently performing studies using elegant techniques developed by others [166–168], to obtain evidence as to how morphine and fentanyl diminish the clearance of fluid from alveoli and reduce amiloride-sensitive transepithelial Na⁺ transport, and the mechanism by which SNO-L-CYS modulates these effects.

4.5. **Effects of SNO-L-CYS on morphine-induced changes in MAP**

As expected, the injection of morphine elicited a sustained decrease in MAP in the vehicle-treated rats. This is consistent with reports that systemic administration of morphine elicits complex dose-dependent effects on hemodynamic parameters and baroreceptor reflex activity in both humans and animals, including rats, where hypotension is a commonly reported phenomenon [75,169–175]. A complicated finding was that morphine caused a sustained reversal of the hypotension in rats receiving the infusion of SNO-L-CYS. We have no direct knowledge of the mechanisms by which this response occurs. Parra et al. [176], reported that morphine had minimal effects on the contractile status of resting (untreated) aortic strips isolated from rats. However, when the vasoconstrictor effects of the sympathetic neurotransmitter, norepinephrine, were allowed to wane, a process that most likely involves the release of endothelium-derived relaxing factors [177–180], the application of morphine elicited sustained concentration- and μ-OR-dependent vasoconstrictor responses by mechanisms that are yet to be determined. As such, it is possible that infusion of the endogenous endothelium-derived relaxing factor, SNO-L-CYS [80,96,100], to the isoflurane-anesthetized rats described in this study alters μ-OR-dependent signaling processes in vascular smooth muscle, such that the subsequent injection of morphine elicits vasoconstrictor responses, thereby producing the observed time-dependent elevation of MAP compared to prior SNO-L-CYS-infusion levels.

4.6. **Effects of SNO-L-CYS on morphine-induced changes in antinociception**

There is now considerable evidence that nitrosyl factors play vital roles in the antinociceptive actions of morphine [62–67,181,182]. A variety of elegant studies in rats and mice have delineated some of these roles [130,181], and have shown that morphine antinociception is lost in neuronal NOS knock-out mice [181] and that this antinociception involves the initial stimulation of phosphatidylinositol-4,5-bisphosphate 3-kinase γ (PI₃Kγ)-protein kinase B (PKB/Alt) pathway that leads to activation of neuronal NOS and ultimately the increased activation of ATP-dependent K⁺-channels (Kₐ₅P-channels) [182]. Our finding that the antinociceptive potency of morphine was enhanced in rats receiving SNO-L-CYS infusion, but not those receiving infusions of L-cysteine and SNO-D-CYS, points to stereoselectivity for SNO-L-CYS. Whether the effects of SNO-L-CYS involve actions in the above pathway are not known, although Numajiri et al. [183], found that morphine signaling via PI₃Kγ-PKB/Alt involves S-nitrosylation of PKB and a phosphatase with high sequence homology to tensin (PTEN), which regulates PI₃Kγ signaling. An extensive
review of the literature found that while nitrosyl factors exert numerous effects that involve changes in $K_{ATP}$-channel activity [184], there is no evidence for direct S-nitrosylation of this ion-channel. With respect to disease processes that may involve S-nitrosothiols, it is known that the analgesic potency of opioids is enhanced upon development of sepsis [185,186], a pathological condition which is associated with greatly enhanced levels of circulating S-nitrosothiols [187].

### 4.7. Study limitations and conclusions

With respect to the study limitations, the findings that the ability of morphine to adversely affect ventilatory parameters, A-a gradient (i.e., the index of gas exchange in alveoli), and arterial blood gas chemistry (i.e., pH, $pO_2$, $pCO_2$, $so_2$) is markedly reduced in isoflurane-anesthetized adult male Sprague Dawley rats that were receiving an intravenous infusion of SNO-L-CYS (1 μmol/kg/min, IV), needs to be confirmed in freely-moving rats that are unanesthetized. Moreover, the potency and efficacy of SNO-L-CYS needs to be established in dose-response studies to establish whether lower infusion concentrations of SNO-L-CYS are efficacious. Another important limitation of this study is the lack of evidence as to the efficacy of SNO-L-CYS in naïve female rats and female rats given morphine with the knowledge that females often display qualitatively and quantitatively different responses to opioids than males [133,188]. Yet another major limitation in this study is the lack of understanding of the molecular mechanisms by which SNO-L-CYS modulates the pharmacological actions of morphine. Currently we are studying the degree to which the systemic administration of morphine generates S-nitrosothiols in central (e.g., the NTS) and peripheral (e.g., the carotid body) structures in rats using our capacitive sensor technology [189], and whether systemic administration of morphine alters the S-nitrosylation status of central (e.g., the NTS) and peripheral (e.g., the carotid body) structures using NADPH diaphorase histochemistry [96].

In conclusion, this study demonstrates that the adverse effects of morphine on ventilation, ABG chemistry, and A-a gradient were markedly reduced in isoflurane-anesthetized male Sprague Dawley rats that were receiving an intravenous infusion of SNO-L-CYS, but not L-cysteine or SNO-D-CYS. Moreover, we also found that the antinociceptive effects of morphine were augmented in rats receiving the SNO-L-CYS infusion, but not infusions of L-cysteine or SNO-D-CYS. The ability of SNO-L-CYS to exert these effects may involve (i) stereoselective processes, including the activation of membrane signaling proteins [14,22,44,190,191], and/or (ii) intracellular entry via an L-amino acid transporter system, which then allows modulation of intracellular signaling pathways [101, 102].

Based on findings that peripherally restricted μ-OR antagonists (e.g., naloxone methiodide) markedly affect the cardiorespiratory and antinociceptive actions of opioids [76], we also conclude that the ability of SNO-L-CYS to modulate the effects of morphine involves the interaction with both peripheral and central μ-OR signaling pathways. For instance, the ability of morphine to reverse SNO-L-CYS-induced hypotension suggests a remarkable and unexpected interaction between S-nitrosothiol- and μ-OR-signaling pathways. Our findings provide the first direct evidence that circulating SNO-L-CYS attenuates the adverse actions of morphine on breathing. A-a gradient (i.e., gas exchange in the lungs), and arterial blood-gas chemistry in anesthetized rats. Another key finding of this study was that the

*Biomed Pharmacother. Author manuscript; available in PMC 2022 September 11.*
Antinociceptive actions of morphine were enhanced in freely-moving rats receiving the infusion of SNO-L-CYS. Additionally, the findings that infusions of L-cysteine or SNO-D-CYS were not able to replicate the above actions of SNO-L-CYS strongly suggest that the L-S-nitrosothiol moiety is the active molecule, and that it acts via stereoselective mechanisms. Conclusively, our findings suggest that the presence/bioavailability of SNO-L-CYS, and perhaps the S-nitrosylation status of proteins in general, may play a fundamental role in the expression of the pharmacological effects of morphine and presumably other opioids, such as fentanyl [71]. As such, conditions and disease states that favor the formation or degradation of S-nitrosothiols [2,18,23,31,105,108,117,187] may be significant for determining the efficacy of the pharmacological actions of opioids. The effects of morphine on the different physiological processes examined in this study (ventilation, alveolar gas exchange and antinociception) may have different mechanisms based on differential expression patterns of opioid receptors, μ-ORs, δ-ORs and κ-ORs, within the brain [192–198] and periphery [199–201]. The μ-OR, which is the major receptor for morphine [129–134]), is widely expressed in central [192,193,196,197] and peripheral [199–201] nervous systems. Within the central nervous system, μ-ORs are expressed in different neuron types (excitatory and inhibitory) and in astroglia [192,193,196,197]. The differential expression of μ-ORs in excitatory and inhibitory neurons may play important roles in the effects of morphine on the different physiological processes under investigation in the present study, and therefore may be a major player in how SNO-L-CYS modulated the effects of morphine.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgements**

The authors wish to thank the staff at the animal care facilities at the University of Virginia, Case Western Reserve University and Galleon Pharmaceuticals, Inc., for their expert assistance with the care of the animals. The authors also wish to thank Mr. David Kalergis (CEO, Atelerix Life Sciences) for his help with clinical perspectives related to the present findings and for providing text.

**Funding**

These studies were supported in part by grants from Galleon Pharmaceuticals, Inc. (to SJL), NIH PO1HL101871 (to BG and SJL) and NIDA U01DA051373 (to SJL).

**Conflict of Interest Statement**

The authors declare that this study received funding from Galleon Pharmaceuticals, Inc. and that Santhosh M. Baby was employed by the company Galleon Pharmaceuticals, Inc. The leadership of the company was not directly involved in this study as a commercial entity. Only the principal scientists of the company were involved in the study design, collection, analysis, interpretation of data, the writing of this article, and the decision to submit it for publication. The remaining authors declare that the research described in this manuscript was performed in the complete absence of commercial or financial relationships that could be construed as a potential conflict of interest.

**Data Availability Statement**

The corresponding author will provide the datasets generated from this study upon email request to sjl78@case.edu.
**Abbreviations:**

- A-a gradient: Alveolar-arterial gradient
- ABG: arterial blood-gas chemistry
- DAMGO: D-Ala², N-MePhe⁴, Gly-ol-δ-enkephalin
- δ-OR: δ-opioid receptor
- fr: frequency of breathing
- K$_{ATP}$-channels: ATP-dependent K$^+$-channels
- L-NA: L-nitro-arginine
- L-NAME: N$^G$-nitro-L-arginine methyl ester
- MAP: mean arterial blood pressure
- Ve: minute ventilation
- μ-OR: μ-opioid receptor
- NO: nitric oxide
- NTS: nucleus tractus solitarius
- PI$_3$Kγ: phosphatidylinositol-4,5-bisphosphate 3-kinase γ
- PKB/Akt: protein kinase B
- SNO-D-CYS: S-nitroso-D-cysteine
- SNO-L-CYS: S-nitroso-L-cysteine
- TF latency: tail-flick withdrawal latency
- Vt: tidal volume

**References**

[1]. Lei SZ, Pan ZH, Aggarwal SK, Chen HS, Hartman J, Sucher NJ, Lipton SA, Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex, Neuron 8 (1992) 1087–1099, 10.1016/0896-6273(92)90130-6. [PubMed: 1376999]

[2]. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, Loscalzo J, Singel DJ, Stamler JS, A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds, Nature 364 (1993) 626–632, 10.1038/364626a0. [PubMed: 8394509]

[3]. Lipton SA, Singel DJ, Stamler JS, Nitric oxide in the central nervous system, Prog. Brain Res 103 (1994) 359–364, 10.1016/s0079-6123(08)61149-8. [PubMed: 7886218]

[4]. Takahashi H, Shin Y, Cho SJ, Zago WM, Nakamura T, Gu Z, Ma Y, Furukawa H, Liddington R, Zhang D, Tong G, Chen HS, Lipton SA, Hypoxia enhances S-nitrosylation-mediated NMDA receptor inhibition via a thiol oxygen sensor motif, Neuron 53 (2007) 53–64, 10.1016/j.neuron.2006.11.023. [PubMed: 17196530]

[5]. Tegeder I, Scheving R, Wittig I, Geisslinger G, SNO-ing at the nociceptive synapse, Pharm. Rev 63 (2011) 366–389, 10.1124/pr.110.004200. [PubMed: 21436345]
[6]. Raju K, Doulias PT, Evans P, Krizman EN, Jackson JG, Horyn O, Daikhin Y, Nissim I, Yudkoff M, Nissim I, Sharp KA, Robinson MB, Ischiropoulos H, Regulation of brain glutamate metabolism by nitric oxide and S-nitrosylation, Sci. Signal 8 (2015) ra68, 10.1126/scisignal.aaa4312. [PubMed: 26152695]

[7]. Tarasenko AS, The effect of nitric oxide on synaptic vesicle proton gradient and mitochondrial potential of brain nerve terminals, Ukr. Biochem. J 87 (2015) 64–75, 10.15407/uhbj87.06.064.

[8]. Nakamura T, Lipton SA, Protein S-nitrosylation as a therapeutic target for neurodegenerative diseases, Trends Pharm. Sci. 37 (2016) 73–84, 10.1016/j.tips.2015.10.002. [PubMed: 2670925]

[9]. Meller ST, Lewis SJ, Bates JN, Brody MJ, Gebrhart GF, Is there a role for an endothelium-derived relaxing factor in nociception, Brain Res. 531 (1990) 342–345, 10.1016/0006-8993(90)90798-g. [PubMed: 2289134]

[10]. Matsuda T, Bates JN, Lewis SJ, Abboud FM, Chapleau MW, Modulation of baroreceptor activity by nitric oxide and S-nitrosothiols, Circ. Res. 76 (1995) 426–433, 10.1161/01.res.76.3.426. [PubMed: 7859388]

[11]. Savidge TC, S-nitrosothiol signals in the enteric nervous system: lessons learnt from big brother, Front. Neurosci 5 (2011) 31, 10.3389/fnins.2011.00031. [PubMed: 21441985]

[12]. Lee J, Nelson MT, Rose KE, Todorovic SM, Redox mechanism of S-nitrosothiol modulation of neuronal CaV3.2 T-type calcium channels, Mol. Neurobiol 48 (2013) 274–280, 10.1007/s12035-013-8493-8. [PubMed: 23813099]

[13]. Tooker RE, Vigh J, Light-evoked S-nitrosylation in the retina, J. Comp. Neuro. 523 (2015) 2082–2110, 10.1002/cne.23780. [PubMed: 25823749]

[14]. Gaston B, Smith L, Bosch J, Seckler J, Kunze D, Kisler J, Marozkina N, Hodges CA, Wintrobe P, McGee K, Marozkina TS, Burton ST, Lewis T, Strassmaier T, Getsy P, Bates JN, Lewis SJ, Voltage-gated potassium channel proteins and stereoselective S-nitroso-L-cysteine signaling, JCI Insight 5 (2020), e134174, 10.1172/jci.insight.134174.

[15]. Mellion BT, Ignarro LJ, Myers CB, Ohlstein EH, Ballot BA, Hyman AL, Kadowitz PJ, Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation, Mol. Pharm 23 (1983) 653–664.

[16]. Travis MD, Stoll LL, Bates JN, Lewis SJ, L- and D-S-nitroso-beta,beta-dimethylcysteine differentially increase cGMP in cultured vascular smooth muscle cells, Eur. J. Pharm 318 (1996) 47–53, 10.1016/s0014-2999(96)00719-4.

[17]. Severina IS, Bussygina OG, Pyatakova NV, Malenkova IV, Vanin AF, Activation of soluble guanylate cyclase by NO donors–S-nitrosothiols, and dinitrosyl-iron complexes with thiol-containing ligands, Nitric Oxide 8 (2003) 155–163, 10.1016/s1089-8603(03)00002-8. [PubMed: 12826064]

[18]. Lima B, Forrester MT, Hess DT, Stamler JS, S-nitrosylation in cardiovascular signaling, Circ. Res 106 (2010) 633–646, 10.1161/CIRCRESAHA.109.207381. [PubMed: 20203313]

[19]. Martínez-Ruiz A, Araújo IM, Izquierdo-Álvarez A, Hernansanz-Agustín P, Lamas S, Serrador JM, Specificity in S-nitrosylation: a short-range mechanism for NO signaling, Antioxid. Redox Signal 19 (2013) 1220–1235, 10.1089/ars.2012.5066. [PubMed: 23157283]

[20]. Marozkina NV, Gaston B, Nitrogen chemistry and lung physiology, Annu. Rev. Physiol 77 (2015) 431–452, 10.1146/annurev-physiol-021113-170352. [PubMed: 25668023]

[21]. Vanin AF, What is the mechanism of nitric oxide conversion into nitrosonium ions ensuring S-nitrosating processes in living organisms, Cell Biochem. Biophys 77 (2019) 279–292, 10.1007/s12013-019-00886-1. [PubMed: 31586291]

[22]. Jokovic PM, Doctor A, Gaston B, Todorovic SM, Functional regulation of T-type calcium channels by s-nitrosothiols in the rat thalamus, J. Neurophysiol 97 (2007) 2712–2721, 10.1152/jn.00926.2006. [PubMed: 17287440]

[23]. Foster MW, Hess DT, Stamler JS, Protein S-nitrosylation in health and disease: a current perspective, Trends Mol. Med 15 (2009) 391–404, 10.1016/j.molmed.2009.06.007. [PubMed: 19726230]
[24]. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH, Protein S-nitrosylation: a physiological signal for neuronal nitric oxide, Nat. Cell Biol 3 (2001) 193–197, 10.1038/35055104. [PubMed: 11175752]

[25]. Rudkouskaya A, Sim V, Shah AA, Feustel PJ, Jourd’heuil D, Mongin AA, Long-lasting inhibition of presynaptic metabolism and neurotransmitter release by protein S-nitrosylation, Free Radic. Biol. Med 49 (2010) 757–769, 10.1016/j.freeradbiomed.2010.05.032. [PubMed: 20633346]

[26]. Marozkina NV, Gaston B, S-Nitrosylation signaling regulates cellular protein interactions, Biochim. Biophys. Acta 1820 (2012) 722–729, 10.1016/j.bbagen.2011.06.017. [PubMed: 21745537]

[27]. Marozkina N, Gaston B, An update on thiol signaling: S-nitrosothiols, hydrogen sulfide and a putative role for thionitrous acid, Antioxidants 9 (2020) 225, 10.3390/antiox9030225.

[28]. Anand P, Hausladen A, Wang YJ, Zhang GF, Stomberski C, Brunengraber H, Hess DT, Stamler JS, Identification of S-nitroso-CoA reductases that regulate protein S-nitrosylation, Proc. Natl. Acad. Sci. USA 111 (2014) 18572–18577, 10.1073/pnas.1417816112. [PubMed: 25512491]

[29]. Pires da Silva M, de Almeida Moraes DJ, Mecawi AS, Rodrigues J, Varanda WA, Nitric oxide modulates HCN channels in magnocellular neurons of the supraoptic nucleus of rats by an S-nitrosylation-dependent mechanism, J. Neurosci 36 (2016) 11320–11330, 10.1523/JNEUROSCI.1588-16.2016. [PubMed: 27807172]

[30]. Wynia-Smith SL, Smith BC, Nitrosothiol formation and S-nitrosation signaling through nitric oxide synthases, Nitric Oxide 63 (2017) 52–60, 10.1016/j.niox.2016.10.001. [PubMed: 27720836]

[31]. Stomberski CT, Hess DT, Stamler JS, Protein S-nitrosylation: determinants of specificity and enzymatic regulation of S-nitrosothiol-based signaling, Antioxid. Redox Signal 30 (2019) 1331–1351, 10.1089/ars.2017.7403. [PubMed: 29130312]

[32]. Lipton AJ, Johnson MA, Macdonald T, Lieberman MW, Gozal D, Gaston B, S-nitrosothiols signal the ventilatory response to hypoxia, Nature 413 (2001) 171–174, 10.1038/35093117. [PubMed: 11557982]

[33]. Ohta H, Bates JN, Lewis SJ, Actions of S-nitrosocysteine in the nucleus tractus solitarii are unrelated to release of nitric oxide, Brain Res. 746 (1997) 98–104, 10.1016/s0006-8993(96)01188-2. [PubMed: 9037488]

[34]. Davisson RL, Bates JN, Johnson AK, Lewis SJ, Use-dependent loss of acetylcholine and bradykinin-mediated vasodilation after nitric oxide synthase inhibition. Evidence for preformed stores of nitric oxide-containing factors in vascular endothelial cells, Hypertension 28 (1996) 354–360, 10.1161/01.hyp.28.3.354. [PubMed: 8794816]
[41]. Davisson RL, Shaffer RA, Johnson AK, Lewis SJ, Use-dependent loss of active sympathetic neurogenic vasodilation after nitric oxide synthase inhibition in conscious rats. Evidence for the presence of preformed stores of nitric oxide-containing factors, Hypertension 28 (1996) 347–353, 10.1161/01.hyp.28.3.347. [PubMed: 8794815]

[42]. Travis MD, Hoque A, Bates JN, Lewis SJ, Blockade of voltage-sensitive Ca^{2+}-channels markedly diminishes nitric oxide- but not L-S-nitrosocysteine- or endothelium-dependent vasodilation in vivo, Eur. J. Pharm 408 (2000) 289–298, 10.1016/s0014-2999(00)00792-5.

[43]. Lewis SJ, Travis MD, Hashmi-Hill MP, Sandock K, Robertson TP, Bates JN, Differential effects of ouabain on the vasodilator actions of nitric oxide and S-nitrosothiols in vivo: relevance to the identity of EDRF/EDHF, Vasc. Pharm 45 (2006) 383–394, 10.1016/j.vph.2006.06.008.

[44]. Travis MD, Lewis SJ, Apparent association of MK-801-sensitive ion channels with L-S-nitrosocysteine recognition sites in the hindlimb vasculature of the rat, Eur. J. Pharm 407 (2000) 309–312, 10.1016/s0014-2999(00)00710-x.

[45]. Hoque A, Bates JN, Lewis SJ, Vascular acetylcholine and K^+ channel modulation of nitric oxide- and L-S-nitrosocysteine-mediated vasodilation in vivo, Eur. J. Pharm 384 (1999) 169–172, 10.1016/s0014-2999(99)00686-x.

[46]. Hoque A, Bates JN, Lewis SJ, Redox regulation of S-nitrosocysteine-mediated vasodilation in vivo, Eur. J. Pharm 408 (2000) 195–198, 10.1016/s0014-2999(00)00779-2.

[47]. Graves JE, Bates JN, Kooy NW, Lewis SJ, Vasodilator actions of the endothelium-derived relaxing factor L-S-nitrosocysteine in anaesthetized rats are markedly diminished by peroxynitrite, Clin. Exp. Pharm. Physiol 32 (2005) 1137–1141, 10.1111/j.1440-1681.2005.04310.x.

[48]. Lewis SJ, Hoque A, Bates JN, Differentiation of L- and D-S-nitrosothiol recognition sites in vivo, J. Cardiovasc. Pharm 46 (2005) 660–671, 10.1097/01.jcp.0000181714.94827.5d.

[49]. Lewis SJ, Graves JE, Bates JN, Kooy NW, Peroxynitrite elicits dysfunction of stereoselective S-nitrosothiol recognition sites, J. Cardiovasc. Pharm 46 (2005) 637–645, 10.1097/01.jcp.0000181717.87204.2f.

[50]. Toda N, Kishioka S, Hatano Y, Toda H, Modulation of opioid actions by nitric oxide signaling, Anesthesiology 110 (2009) 166–181, 10.1097/ALN.0b013e318191416a.[PubMed: 19104184]

[51]. Toda N, Kishioka S, Hatano Y, Toda H, Interactions between morphine and nitric oxide in various organs, J. Anesth 23 (2009) 554–568, 10.1007/s00540-009-0793-9.[PubMed: 19921366]

[52]. Rodríguez-Muñoz M, Garzón J, Nitric oxide and zinc-mediated protein assemblies involved in mu opioid receptor signaling, Mol. Neurobiol 48 (2013) 769–782, 10.1007/s12035-013-8465-z.[PubMed: 23666425]

[53]. Pol O, The involvement of the nitric oxide in the effects and expression of opioid receptors during peripheral inflammation, Curr. Med. Chem 14 (2007) 1945–1955, 10.2174/092986707781368469.[PubMed: 17691937]

[54]. Ozdemir E, Bagcivan I, Durmus N, Altun A, Gursoy S, The nitric oxide-cGMP signaling pathway plays a significant role in tolerance to the analgesic effect of morphine, Can. J. Physiol. Pharm 89 (2011) 89–95, 10.1139/y10-109.

[55]. Durmus N, Bagcivan I, Ozdemir E, Altun A, Gursoy S, Soluble guanylyl cyclase activators increase the expression of tolerance to morphine analgesic effect, Bratisl. Lek. Listy 115 (2014) 334–339, 10.4149/bll_2014_066.[PubMed: 25023422]

[56]. Kissin I, Bright CA, Bradley EL Jr., Acute tolerance to continuously infused alfentanil: the role of cholecystokinin and N-methyl-D-aspartate-nitric oxide systems, Anesth. Analg 91 (2000) 110–116, 10.1097/00000539-200007000-00021.[PubMed: 10866896]

[57]. Lu Y, Hu J, Zhang Y, Dong C, Spinal neuronal NOS activation mediates intrathecal fentanyl preconditioning induced remote cardioprotection in rats, Int. Immunopharm 19 (2014) 127–131, 10.1016/j.intimp.2014.01.013.

[58]. Someya E, Mori A, Sakamoto K, Ishii K, Nakahara T, Stimulation of mu-opioid receptors dilates retinal arterioles by neuronal nitric oxide synthase-derived nitric oxide in rats, Eur. J. Pharm 803 (2017) 124–129, 10.1016/j.ejphar.2017.03.043.
[59]. Erkent U, Iskit AB, Onur R, Ilhan M, The effect of nitric oxide on fentanyl and haloperidol-induced catalepsy in mice, Eur. J. Anaesthesiol 23 (2006) 580–585, 10.1017/S0265021206000226. [PubMed: 16507184]

[60]. Sahin AS, Duman A, Atalik EK, Ogün CO, Sahin TK, Erol A, Ozergin U, The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro, J. Cardiothorac. Vasc. Anesth 19 (2005) 197–200, 10.1053/j.vca.2005.01.031. [PubMed: 15868528]

[61]. Kaye AD, Hoover JM, Ibrahim IN, Phelps J, Baluch A, Fields A, Huffman S, Analysis of the effects of fentanyl in the feline pulmonary vascular bed, Am. J. Ther 13 (2006) 478–484, 10.1097/01.mjt.0000178338.43545.3a. [PubMed: 17122527]

[62]. Pelligrino DA, Laurito CE, VadeBoncouer TR, Nitric oxide synthase inhibition modulates the ventilatory depressant and antinociceptive actions of fourth ventricular infusions of morphine in the awake dog, Anesthesiology 85 (1996) 1367–1377, 10.1097/00000542-199612000-00018. [PubMed: 8968184]

[63]. Maegawa FA, Tonussi CR, The L-arginine/nitric oxide/cyclic-GMP pathway apparently mediates the peripheral antiinflammatory action of fentanyl in rats, Braz. J. Med. Biol. Res 36 (2003) 1701–1707, 10.1590/s0100-879x2003001200012. [PubMed: 14666255]

[64]. Cury Y, Picolo G, Gutierrez VP, Ferreira SH, Pain and analgesia: the dual effect of nitric oxide in the nociceptive system, Nitric Oxide 25 (2011) 243–254, 10.1016/j.niox.2011.06.004. [PubMed: 21723953]

[65]. Hervera A, Negrete R, Leánez S, Martín-Campos JM, Pol O, Peripheral effects of morphine and expression of mu-opioid receptors in the dorsal root ganglia during neuropathic pain: nitric oxide signaling, Mol. Pain 7 (2011) 25, 10.1186/1744-8069-7-25. [PubMed: 21486477]

[66]. Mehanna MM, Domiati S, Nakkash Chmaisse H, El Mallah A, Antinociceptive effect of tadalafil in various pain models: involvement of opioid receptors and nitric oxide cyclic GMP pathway, Toxicol. Appl. Pharm 352 (2018) 170–175, 10.1016/j.taap.2018.05.013.

[67]. Ortiz MI, Carinño-Cortés R, Castañeda-Hernández G, Participation of the opioid receptor-nitric oxide-cyclic GMP-K+ channel pathway in the peripheral antinociceptive effect of nalbuphine and buprenorphine in rats, Can. J. Physiol. Pharm 98 (2020) 753–762, 10.1139/cjpp-2020-0104.

[68]. Bilfinger TV, Fimiani C, Stefano GB, Morphine’s immunoregulatory actions are not shared by fentanyl, Int. J. Cardiol 64 (Suppl. 1) (1998) S61–S66, 10.1016/S0167-5273(98)00037-0. [PubMed: 9687094]

[69]. Jan WC, Chen CH, Hsu K, Tsai PS, Huang CJ, L-type calcium channels and μ-opioid receptors are involved in mediating the anti-inflammatory effects of naloxone, J. Surg. Res 167 (2011) e263–e272, 10.1016/j.jss.2010.03.039. [PubMed: 20605582]

[70]. Teppema L, Sartoon E, Dahan A, Oliveier CN, The neuronal nitric oxide synthase inhibitor 7-nitroindazole (7-NI) and morphine act independently on the control of breathing, Br. J. Anaesth 84 (2000) 190–196, 10.1093/oxfordjournals.bja.a013402. [PubMed: 10743452]

[71]. Seckler JM, Grossfield A, May WJ, Getsy PM, Lewis SJ, Nitrosyl factors play a vital role in the ventilatory depressant effects of fentanyl in unanesthetized rats, Biomed. Pharmacother 146 (2022), 112571, 10.1016/j.biopharm.2021.112571. [PubMed: 34953397]

[72]. Whalen EJ, Foster MW, Matsumoto A, Ozawa K, Violin JD, Que LG, Nelson CD, Benhar M, Keys JR, Rockman HA, Koch WJ, Daaka Y, Lefkowitz RJ, Stamler JS, Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2, Cell 129 (2007) 511–522, 10.1016/j.cell.2007.02.046. [PubMed: 17482545]

[73]. Nozik-Grayck E, Whalen EJ, Stamler JS, McMahon TJ, Chitano P, Piantadosi CA, S-nitrosothiolamine inhibits alpha1-adrenergic receptor-mediated vasoconstriction and ligand binding in pulmonary artery, Am. J. Physiol. Lung Cell. Mol. Physiol 290 (2006) L136–L143, 10.1152/ajplung.00230.2005. [PubMed: 16126786]

[74]. Kokkola T, Savinainen JR, Mönkkönen KS, Retamal MD, Laitinen JT, S-nitrosothiols modulate G protein-coupled receptor signaling in a reversible and highly receptor-specific manner, BMC Cell Biol. 6 (2005) 21, 10.1186/1471-2121-6-21. [PubMed: 15850493]
[75]. Baby SM, Discala JF, Gruber R, Getsy PM, Cheng F, Damron DS, Lewis SJ, Tempol reverses the negative effects of morphine on arterial blood-gas chemistry and tissue oxygen saturation in freely-moving rats, Front. Pharm 12 (2021), 749084, 10.3389/fphar.2021.749084.

[76]. Henderson F, May WJ, Gruber RB, Discala JF, Puskovic V, Young AP, Baby SM, Lewis SJ, Role of central and peripheral opiate receptors in the effects of fentanyl on analgesia, ventilation and arterial blood-gas chemistry in conscious rats, Respir. Physiol. Neurobiol 191 (2014) 95–105, 10.1016/j.resp.2013.11.005. [PubMed: 2348037]

[77]. Gaston B, Baby SM, May WJ, Young AP, Grossfield A, Bates JN, Seckler JM, Wilson CG, Lewis SJ, D-Cystine di(m)ethyl ester reverses the deleterious effects of morphine on ventilation and arterial blood-gas chemistry while promoting antinociception, Sci. Rep 11 (2021) 10038, 10.1038/s41598-021-86458-x. [PubMed: 33772077]

[78]. Lewis SJ, Meller ST, Brody MJ, Gebhart GF, Reduced nociceptive effects of intravenous serotonin (5-HT) in the spontaneously hypertensive rat, Clin. Exp. Hypertens. A 13 (1991) 1991, 10.3109/10641969109042089.

[80]. Myers PR, Minor RL Jr., Guerra R Jr., Bates JN, Harrison DG, Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide, Nature 345 (1990) 161–163, 10.1038/345161a0. [PubMed: 2110626]

[81]. Wallensteins Z, Zucker CL, Fleiss JL, Some statistical methods useful in circulation research, Circ. Res 47 (1980) 1–9, 10.1161/01.res.47.1.1. [PubMed: 7379260]

[82]. Ludbrook J, Multiple comparison procedures updated. Clin. Exp. Pharmac. Physiol 25 (1998) 1032–1037, 10.1111/j.1440-1681.1998.tb02179.x.

[83]. McHugh ML, Multiple comparison analysis testing in ANOVA, Biochem. Med 21 (2011) 203–209, 10.11613/bm.2011.029.

[84]. Getsy PM, Sundararajan S, May WJ, von Schill GC, McLaughlin DK, Palmer LA, Lewis SJ, Short-term facilitation of breathing upon cessation of hypoxic challenge is impaired in male but not female endothelial NOS knock-out mice, Sci. Rep 11 (2021) 18346. [PubMed: 34526532]

[85]. Weissgerber TL, Garcia-Valencia O, Garovic VD, Milic NM, Winham SJ, Why we need to report more than ‘Data were Analyzed by t-tests or ANOVA’, Elife 7 (2018), e36163 10.7554/eLife.36163. [PubMed: 30574870]

[86]. Stampler JS, Jia L, Eu JP, McMahon TJ, Demchenko IT, Bonaventura J, Gerrert K, Piantadosi CA, Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient, Science 276 (1997) 2034–2037, 10.1126/science.276.5321.2034. [PubMed: 9197264]

[87]. Inoue K, Akaite T, Miyamoto Y, Okamoto T, Sawa T, Otagiri M, Suzuki S, Yoshimura T, Maeda H, Nitrosothiol formation catalyzed by ceruloplasmin. Implication for cytoprotective mechanism in vivo, J. Biol. Chem 274 (1999) 27069–27075, 10.1074/jbc.274.38.27069. [PubMed: 10480920]

[88]. Singel DJ, Stampler JS, Blood traffic control, Nature 430 (2004) 297, 10.1038/430297a. [PubMed: 15254518]

[89]. Doctor A, Platt R, Sheram ML, Eischeid A, McMahon T, Maxey T, Doherty J, Axelrod M, Kline J, Gurka M, Gow A, Gaston B, Hemoglobin conformation couples erythrocyte S-nitrosothiol content to O2 gradients, Proc. Natl. Acad. Sci. USA 102 (2005) 5709–5714, 10.1073/pnas.0407490102. [PubMed: 15824313]

[90]. Gaston B, Singel D, Doctor A, Stampler JS, S-nitrosothiol signaling in respiratory biology, Am. J. Respir. Crit. Care Med 173 (2006) 1186–1193, 10.1164/rcrm.200510-1584PP. [PubMed: 16528016]

[91]. Straub AC, Lohman AW, Billaud M, Johnstone SR, Dwyer ST, Lee MY, Bortz PS, Best AK, Columbus L, Gaston B, Isakson BE, Endothelial cell expression of haemoglobin alpha regulates nitric oxide signalling, Nature 491 (2012) 473–477, 10.1038/nature11626. [PubMed: 23123858]

[92]. Haldar SM, Stampler JS, S-nitrosoylation: integrator of cardiovascular performance and oxygen delivery, J. Clin. Invest 123 (2013) 101–110, 10.1172/JCI62854. [PubMed: 23281416]
[93]. Zhang R, Hess DT, Qian Z, Hausladen A, Fonseca F, Chaube R, Reynolds JD, Stamler JS, Hemoglobin βCys93 is essential for cardiovascular function and integrated response to hypoxia, Proc. Natl. Acad. Sci. USA 112 (2015) 6425–6430, 10.1073/pnas.1502285112. [PubMed: 25810253]

[94]. Leo F, Suvorava T, Heuser SK, Li J, LoBue A, Barbarino F, Piragine E, Schneckmann R, Hutzler B, Good ME, Fernandez BO, Vornholz L, Rogers S, Doctor A, Grandch M, Stegbauer J, Wetzberg E, Feelisch M, Lundberg JO, Isakson BE, Kelm M, Cortese-Krott MM, Red blood cell and endothelial eNOS independently regulate circulating nitric oxide metabolites and blood pressure, Circulation 144 (2021) 870–889, 10.1161/CIRCULATIONAHA.120.049606. [PubMed: 34229449]

[95]. Premont RT, Reynolds JD, Zhang R, Stamler JS, Red blood cell-mediated S-nitrosohemoglobin-dependent vasodilation: lessons learned from a β-globin Cys93 knock-in mouse, Antioxid. Redox Signal 34 (2021) 936–961, 10.1089/ars.2020.8153. [PubMed: 32597195]

[96]. Seckler JM, Shen J, Lewis THJ, Abdulameer MA, Zaman K, Palmer LA, Bates JN, Jenkins MW, Lewis SJ, NADPH diaphorase detects S-nitrosylated proteins in aldehyde-treated biological tissues, Sci. Rep 10 (2020) 21088, 10.1038/s41598-020-7107-6. [PubMed: 32373578]

[97]. Gaston B, Sears S, Woods J, Hunt J, Ponaman M, McMahon T, Stamler JS, Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure, Lancet 351 (1998) 1317–1319, 10.1016/S0140-6736(97)07485-0. [PubMed: 9643794]

[98]. Janocha AJ, Koch CD, Tiso M, Ponchia A, Doctor A, Gibbons L, Gaston B, Beall CM, Erzurum SC, Nitric oxide during altitude acclimatization, N. Engl. J. Med 365 (2011) 1942–1944, 10.1056/NEJMc1107887. [PubMed: 22087700]

[99]. Ware LB, Magarik JA, Wickersham N, Cunningham G, Rice TW, Christmas BW, Wheeler AP, Bernard GR, Summar ML, Low plasma citrulline levels are associated with acute respiratory distress syndrome in patients with severe sepsis, Crit. Care 17 (2013) R10, 10.1186/cc11934. [PubMed: 23237349]

[100]. Kukreja RC, Wei EP, Kontos HA, Bates JN, Nitric oxide and S-nitroso-L-cysteine as endothelium-derived relaxing factors from acetylcholine in cerebral vessels in cats, Stroke 24 (1993), 10.1161/01.str.24.12.2010 (2010–2014; discussion 2014–2015).

[101]. Nemoto T, Shimma N, Horie S, Saito T, Okuma Y, Nomura Y, Murayama T, Involvement of the system L amino acid transporter on uptake of S-nitroso-L-cysteine, an endogenous S-nitrosothiol, in PC12 cells, Eur. J. Pharm 458 (2003) 17–24, 10.1016/s0014-2999(02)02699-7.

[102]. Li S, Whorton AR, Functional characterization of two S-nitroso-L-cysteine transporters, which mediate movement of NO equivalents into vascular cells, Am. J. Physiol. Cell Physiol 292 (2007) C1263–C1271, 10.1152/ajpcell.00382.2006. [PubMed: 17092994]

[103]. Matsumoto A, Comatas KE, Liu L, Stamler JS, Screening for nitric oxide-dependent protein-protein interactions, Science 301 (2003) 657–661, 10.1126/science.1079319. [PubMed: 12893946]

[104]. Burwell LS, Nadtochiy SM, Tompkins AJ, Young S, Brookes PS, Direct evidence for S-nitrosation of mitochondrial complex I, Biochem. J 394 (2006) 627–634, 10.1042/BJ20051435. [PubMed: 16371007]

[105]. Forrester MT, Thompson JW, Foster MW, Nogueira L, Moseley MA, Stamler JS, Proteomic analysis of S-nitrosylation and denitrosylation by resin-assisted capture, Nat. Biotechnol 27 (2009) 557–559, 10.1038/nbt.1545. [PubMed: 19483679]

[106]. Broniowska KA, Hogg N, Differential mechanisms of inhibition of glyceraldehyde-3-phosphate dehydrogenase by S-nitrosothiols and NO in cellular and cell-free conditions, Am. J. Physiol. Heart Circ. Physiol 299 (2010) H1212–H1219, 10.1152/ajpheart.00472.2010. [PubMed: 20675567]

[107]. Iwakiri Y, S-nitrosylation of proteins: a new insight into endothelial cell function regulated by eNOS-derived NO, Nitric Oxide 25 (2011) 95–101, 10.1016/j.niox.2011.04.014. [PubMed: 21554971]

[108]. Seth D, Stamler JS, The SNO-proteome: causation and classifications, Curr. Opin. Chem. Biol 15 (2011) 129–136, 10.1016/j.cbpa.2010.10.012. [PubMed: 21087893]
[109]. Piantadosi CA, Regulation of mitochondrial processes by protein S-nitrosylation, Biochim. Biophys. Acta 1820 (2012) 712–721, 10.1016/j.bbagen.2011.03.008. [PubMed: 21397666]

[110]. Dejanovic B, Schwarz G, Neuronal nitric oxide synthase-dependent S-nitrosylation of gephyrin regulates gephyrin clustering at GABAergic synapses, J. Neurosci 34 (2014) 7763–7768, 10.1523/JNEUROSCI.0531-14.2014. [PubMed: 24899700]

[111]. Lin L, Xu C, Carraway MS, Piantadosi CA, Whorton AR, Li S, RhoA inactivation by S-nitrosylation regulates vascular smooth muscle contractive signaling, Nitric Oxide 74 (2018) 56–64, 10.1016/j.niox.2018.01.007. [PubMed: 29355776]

[112]. George MJ, Shibata EF, Regulation of calcium-activated potassium channels by S-nitrosothiol compounds and cyclic guanosine monophosphate in rabbit coronary artery myocytes, J. Investig. Med 43 (1995) 451–458.

[113]. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA, Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle, Nature 368 (1994) 850–853, 10.1038/368850a0. [PubMed: 7512692]

[114]. Garcia ML, Knaus HG, Munujos P, Slaughter RS, Kaczorowski GJ, Charybdotoxin and its effects on potassium channels, Am. J. Physiol 269 (1995) C1–C10, 10.1152/ajpcell.1995.269.1.C1. [PubMed: 7543240]

[115]. Tsikas D, Sandmann J, Luessen P, Savva A, Rossa S, Stichtenoth DO, Frölich JC, S-Transnitrosylation of albumin in human plasma and blood in vitro and in vivo in the rat, Biochim. Biophys. Acta 1546 (2001) 422–434, 10.1016/s0167-4838(01)00166-2. [PubMed: 11295447]

[116]. Minamiyama Y, Takemura S, Inoue M, Albumin is an important vascular tonus regulator as a reservoir of nitric oxide, Biochem. Biophys. Res. Commun 225 (1996) 112–115, 10.1006/bbrc.1996.1138. [PubMed: 8769102]

[117]. Foster MW, Pawloski JR, Singel DJ, Stamler JS, Role of circulating S-nitrosothiols in control of blood pressure, Hypertension 45 (2005) 15–17, 10.1161/01.HYP.0000150160.41992.71. [PubMed: 15557388]

[118]. Chen SR, Eisenach JC, Pan HL, Intrathecal S-nitroso-N-acetylpenicillamine and L-cysteine attenuate nerve injury-induced allodynia through noradrenergic activation in rats, Neuroscience 101 (759–765) (2000) 2000, 10.1016/s0306-4522(00)00415-2.

[119]. Li X, Rose G, Dongre N, Pan HL, Tobin JR, Eisenach JC, S-nitroso-L-cysteine releases norepinephrine in rat spinal synaptosomes, Brain Res. 872 (2000) 301–307, 10.1016/s0006-8993(00)02551-8. [PubMed: 10924712]

[120]. Zhu X, Li X, Eisenach JC, Spinal norepinephrine release from nitric oxide species is not increased following peripheral nerve injury in rats, Brain Res. 947 (2002) 199–203, 10.1016/s0006-8993(02)02924-4. [PubMed: 12176161]

[121]. Imam MZ, Kuo A, Ghassabian S, Smith MT, Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression, Neuropharmacology 131 (2018) 238–255, 10.1016/j.neuropharm.2017.12.032. [PubMed: 29273520]

[122]. Stein C, New concepts in opioid analgesia, Expert Opin. Investig. Drugs 27 (2018) 765–775, 10.1080/13543784.2018.1516204.

[123]. Birdsong WT, Williams JT, Recent progress in opioid research from an electrophysiological perspective, Mol. Pharm 98 (2020) 401–409, 10.1124/mol.119.119040.

[124]. Diüzen IV, Deridovich II, Kurbatskii RA, Shorin VV, NO-ergic rat brain commissural neurons in the norm and during opiate administration, Morphologia 123 (2003) 24–29.

[125]. Dyuizen IV, Deridovich II, Kurbatskii RA, Shorin VV, NO-ergic neurons of the cervical nucleus of the rat brain in normal conditions and after administration of opiates, Neurosci. Behav. Physiol 34 (2004) 621–626, 10.1023/b:neah.0000028295.15502.2b. [PubMed: 15368911]

[126]. Dyuizen IV, Motavkin PA, Shorin VV, Dynamics of NADPH diaphorase activity in raphe neurons during chronic treatment with opiates, Bull. Exp. Biol. Med 132 (2001) 918–920, 10.1023/a:1013151625135. [PubMed: 11740593]

[127]. Atanasova DY, Dandov AD, Dimitrov ND, Lazarov NE, Histochemical and immunohistochemical localization of nitricergic structures in the carotid body of spontaneously hypertensive rats, Acta Histochem. 122 (2020), 151500, 10.1016/j.acthis.2019.151500. [PubMed: 31918956]
[128]. Mendoza J, Passafaro R, Baby S, Young AP, Bates JN, Gaston B, Lewis SJ, L-Cysteine ethyl ester reverses the deleterious effects of morphine on, arterial blood-gas chemistry in tracheotomized rats, Respir. Physiol. Neurobiol 189 (2013) 136–143, 10.1016/j.resp.2013.07.007. [PubMed: 23892097]

[129]. Dahan A, Aarts L, Smith TW, Incidence, reversal, and prevention of opioid-induced respiratory depression, Anesthesiology 112 (2010) 226–238, 10.1097/ALN.0b013e3181c38c25. [PubMed: 20010421]

[130]. Dahan A, van der Schier R, Smith T, Aarts L, van Velzen M, Niesters M, Averting opioid-induced respiratory depression without affecting analgesia, Anesthesiology 128 (2018) 1027–1037, 10.1097/ALN.0000000000002184. [PubMed: 29553984]

[131]. Boom M, Niesters M, Sarton E, Aarts L, Smith TW, Dahan A, Non-analgesic effects of opioids: opioid-induced respiratory depression, Curr. Pharm. Des 18 (2012) 5994–6004, 10.2174/138161212803582469. [PubMed: 22747535]

[132]. Berkenbosch A, Teppema LJ, Olivier CN, Dahan A, Influences of morphine on the ventilatory response to isocapnic hypoxia, Anesthesiology 86 (1997) 1342–1349, 10.1097/00000542-199706000-00016. [PubMed: 9197304]

[133]. Dahan A, Sarton E, Teppema L, Olivier C, Sex-related differences in the influence of morphine on ventilatory control in humans, Anesthesiology 88 (1998) 903–913, 10.1097/00000542-199804000-00009. [PubMed: 9579498]

[134]. Sarton E, Teppema L, Dahan A, Sex differences in morphine-induced ventilatory depression reside within the peripheral chemoreflex loop, Anesthesiology 90 (1999) 1329–1338, 10.1097/00000542-199905000-00017. [PubMed: 10319781]

[135]. Peat SJ, Hanna MH, Woodham M, Knibb AA, Ponte J, Morphine-6-glucuronide: effects on ventilation in normal volunteers, Pain 45 (1991) 101–104, 10.1016/0304-3959(91)90170-3. [PubMed: 19073762]

[136]. Emery MJ, Groves CC, Kruse TN, Shi C, Terman GW, Ventilation and the response to hypercapnia after morphine in opioid-naive and opioid-tolerant rats, Anesthesiology 124 (2016) 945–957, 10.1097/ALN.0000000000000997. [PubMed: 26734964]

[137]. May WJ, Gruber RB, Discala JF, Puskovic V, Henderson F, Palmer LA, Lewis SJ, Morphine has latent deleterious effects on the ventilatory responses to a hypoxic challenge, Open J. Mol. Integr. Physiol 3 (2013) 166–180, 10.4236/ojmip.2013.34022. [PubMed: 25045993]

[138]. May WJ, Henderson F, Gruber RB, Discala JF, Young AP, Bates JN, Palmer LA, Lewis SJ, Morphine has latent deleterious effects on the ventilatory responses to a hypoxic-hypercapnic challenge, Open. J. Mol. Integr. Physiol 3 (2013) 134–145, 10.4236/ojmip.2013.33019. [PubMed: 25045592]

[139]. Murphy DJ, Joran ME, Grando JC, A non-invasive method for distinguishing central from peripheral nervous system effect of respiratory depressant drugs in conscious rats, Gen. Pharm 26 (1995) 569–575, 10.1016/0306-3623(94)00215-9.

[140]. Zhang Z, Xu F, Zhang C, Liang X, Activation of opioid mu-receptors in caudal medullary raphe region inhibits the ventilatory response to hypercapnia in anesthetized rats, Anesthesiology 107 (2007) 288–297, 10.1097/01.anes.0000270760.46821.67. [PubMed: 17667574]

[141]. Zhang Z, Xu F, Zhang C, Liang X. Opioid mu-receptors in medullary raphe region affect the hypoxic ventilation in anesthetized rats, Resp. Physiol. Neurobiol 168 (2009) 281–288, 10.1016/j.resp.2009.07.015.

[142]. Zhang Z, Zhuang J, Zhang C, Xu F, Activation of opioid μ-receptors in the commissural subdivision of the nucleus tractus solitarius abolishes the ventilatory response to hypoxia in anesthetized rats, Anesthesiology 115 (2011) 353–363, 10.1097/ALN.0b013e318224ec1f. [PubMed: 21716092]

[143]. McQueen DS, Ribeiro JA, Inhibitory actions of methionine-enkephalin and morphine on the cat carotid chemoreceptors, Brit. J. Pharm 71 (1980) 297–305, 10.1111/j.1476-5381.1980.tb10939.x.

[144]. Kirby GC, McQueen DS, Characterization of opioid receptors in the cat carotid body involved in chemosensory depression in vivo, Brit. J. Pharm 88 (1986) 889–898, 10.1111/j.1476-5381.1986.tb16263.x.
[145]. Zimpfer M, Beck A, Mayer N, Raberger G, Steinbereithner K, Effects of morphine on the control of the cardiovascular system by the carotid-sinus-reflex and by the carotid chemoreflex, Anaesthesist 32 (1983) 60–66. [PubMed: 6405654]

[146]. Baby SM, Gruber RB, Young AP, MacFarlane PM, Teppema LJ, Lewis SJ, Bilateral carotid sinus nerve transection exacerbates morphine-induced respiratory depression, Eur. J. Pharm 834 (2018) 17–29, 10.1016/j.ejphar.2018.07.018.

[147]. Henderson F, May WJ, Gruber RB, Young AP, Palmier LA, Gaston B, Lewis SJ, Low-dose morphine elicits ventilatory excitant and depressant responses in conscious rats: role of peripheral mu-opioid receptors, Open J. Mol. Integr. Physiol 3 (2013) 111–124, 10.4236/ojmip.2013.33017. [PubMed: 24900948]

[148]. Szeto HH, Cheng PY, Dwyer G, Decena JA, Wu DL, Cheng Y, Morphine-induced stimulation of fetal breathing: role of mu 1-receptors and central muscarinic pathways, Am. J. Physiol. Regul. Integr. Comp. Physiol 261 (2001) R344–R350, 10.1152/ajpregu.1991.261.2.R344.

[149]. Cheng PY, Wu D, Soong Y, McCabe S, Decena JA, Szeto HH, Role of μ1- and δ-opioid receptors in modulation of fetal EEG and respiratory activity, Am. J. Physiol. Regul. Integr. Comp. Physiol 1993 (265) (1993) R433–R438, 10.1152/ajpregu.1993.265.2.R433.

[150]. Hedenstierna G, Rothen HU, Respiratory function during anaesthesia: effects on gas exchange, Compr. Physiol 2 (2012) 69–96, 10.1002/cphy.c080111. [PubMed: 23728971]

[151]. Di Marco F, Bonacina D, Vassena E, Arisi E, Apostolo A, Banfi C, Centanni S, Agostoni P, Fumagalli R, The effects of anesthesia, muscle paralysis, and ventilation on the lung evaluated by lung diffusion for carbon monoxide and pulmonary surfactant protein B, Anesth. Analg 120 (2015) 373–380, 10.1213/ANE.0000000000000496. [PubMed: 25360481]

[152]. Choi Y, Jang J, Park HS, Pulmonary surfactants: a new therapeutic target in asthma, Curr. Allergy Asthma Rep 20 (2020) 70, 10.1007/s11882-020-00968-8. [PubMed: 32914349]

[153]. Strandberg A, Tokics L, Brismar B, Lundquist H, Hedenstierna G, Constitutional factors promoting development of atelectasis during anaesthesia, Acta Anaesthesiol. Scand 31 (1987) 21–24, 10.1111/j.1399-6576.1987.tb02513.x. [PubMed: 3825472]

[154]. Egbert LD, Bendixen HH, Effect of morphine on breathing pattern. A possible factor in atelectasis, JAMA 188 (1964) 485–488, 10.1001/jama.1964.03060320007001. [PubMed: 14159063]

[155]. De Cosmo G, Aceto P, Gualtieri E, Congedo E, Analgesia in thoracic surgery: review, Minerva Anestesiol. 75 (2009) 393–400. [PubMed: 18953284]

[156]. De Jong A, Verzilli D, Chanques G, Futier E, Jaber S, Preoperative risk and perioperative management of obese patients, Rev. Mal. Respir 36 (2019) 985–1001, 10.1016/j.rmr.2019.01.009. [PubMed: 31521434]

[157]. Guggenberger H, Schroeder TH, Vonthein R, Dieterich HJ, Sherman SK, Eltzschig HK, Remifentanil or sufentanil for coronary surgery: comparison of postoperative respiratory impairment, Eur. J. Anaesthesiol 23 (2006) 832–840, 10.1017/S0265021506000251. [PubMed: 16512971]

[158]. Friedrich S, Raub D, Teja BJ, Neves SE, Thevathanas T, Houle TT, Eikermann M, Effects of low-dose intraoperative fentanyl on postoperative respiratory complication rate: a pre-specified, retrospective analysis, Br. J. Anaesth 122 (2019) e180–e188, 10.1016/j.bja.2019.03.017. [PubMed: 30982564]

[159]. Nowakowski JF, Acute alveolar edema, Emerg. Med. Clin. N. Am 1 (1983) 313–343.

[160]. Guntpalli KK, Acute pulmonary edema, Cardiol. Clin 2 (1984) 183–200. [PubMed: 6443344]

[161]. Rezaiguia-Delclaux S, Jayr C, Luo DF, Saidi NE, Meignan M, Duvaldestin P, Halothane and isoflurane decrease alveolar epithelial fluid clearance in rats, Anesthesiology 88 (1998) 751–760, 10.1097/00000542-199803000-00027. [PubMed: 9523820]

[162]. Kaestle SM, Reich CA, Yin N, Habazettl H, Weimann A, Kuebler WM, Nitric oxide-dependent inhibition of alveolar fluid clearance in hydrostatic lung edema, Am. J. Physiol. Lung Cell. Mol. Physiol 293 (2007) L859–L869, 10.1152/ajplung.00008.2007. [PubMed: 17616651]

[163]. Jain L, Chen XJ, Brown LA, Eaton DC, Nitric oxide inhibits lung sodium transport through a cGMP-mediated inhibition of epithelial cation channels, Am. J. Physiol 274 (1998) L475–L484, 10.1152/ajplung.1998.274.4.L475. [PubMed: 9575865]
[164]. Helms MN, Jain L, Self JL, Eaton DC, Redox regulation of epithelial sodium channels examined in alveolar type 1 and 2 cells patch-clamped in lung slice tissue, J. Biol. Chem 283 (2008) 22875–22883, 10.1074/jbc.M801363200. [PubMed: 18541535]

[165]. Hardiman KM, McNicholas-Bevensee CM, Fortenberry J, Myles CT, Malik B, Eaton DC, Matalon S, Regulation of amiloride-sensitive Na\(^+\) transport by basal nitric oxide, Am. J. Respir. Cell. Mol. Biol 30 (2004) 720–728, 10.1165/rccmb.2003-0325OC. [PubMed: 14607816]

[166]. Berger MM, Rozendal CS, Schieber C, Dehler M, Zügel S, Bardenheuer HJ, Bärtch P, Mairbäurl H, The effect of endothelin-1 on alveolar fluid clearance and pulmonary edema formation in the rat, Anesth. Analg 108 (2009) 225–231, 10.1213/ane.0b013e31818881a8. [PubMed: 19095854]

[167]. Saldías F, Lecuona E, Friedman E, Barnard ML, Ridge KM, Szajdjer JJ, Modulation of lung liquid clearance by isoproterenol in rat lungs, Am. J. Physiol 274 (1998) L694–L701, 10.1152/ajplung.1998.274.5.L694. [PubMed: 9612284]

[168]. Sakuma T, Gu X, Sugita M, Sagawa M, Sakuda M, Toga H, Catecholamine clearance from alveolar spaces of rat and human lungs, Respirat.ion 72 (2005) 189–196, 10.1159/000084051. [PubMed: 15824530]

[169]. Kotrly KJ, Ebert T, Vucins EJ, Roerig DL, Kampine JP, Baroreceptor reflex control of heart rate during morphine sulfate, diazepam, N\(_2\)O/O\(_2\) anesthesia in humans, Anesthesiology 61 (1984) 558–563, 10.1097/00000542-198411000-00015. [PubMed: 6496994]

[170]. Della Puppa A, Ford-Rice F, Snyder FR, Cone E, London ED, Time course of verapamil interaction with morphine effects on physiological parameters in rats, J. Pharm. Pharmaco 41 (1989) 617–623, 10.1111/j.1600-0720.1989.tb06542.x.

[171]. Thornhill JA, Townsend C, Gregor L, Intravenous morphine infusion (IMF) to drug-naive, conscious rats evokes bradycardic, hypotensive effects, but pressor actions are elicited after IMF to rats previously given morphine, Can. J. Physiol. Pharmaco 67 (1989) 222–222, 10.1139/y89-036.

[172]. Thurston CL, Starines A, Randich A, Changes in nociception, arterial blood pressure and heart rate produced by intravenous morphine in the conscious rat, Brain Res. 612 (1993) 70–77, 10.1016/0006-8993(93)91645-9. [PubMed: 8330215]

[173]. Shanazari AA, Aslani Z, Ramshini E, Alaei H, Acute and chronic effects of morphine on cardiovascular system and the baroreflexes sensitivity during severe increase in blood pressure in rats, ARYA Atheroscler. 7 (2011) 111–117. [PubMed: 22577457]

[174]. Zeinivand M, Rahmani MR, Allatavakoli M, Shamsizadeh A, Hassanshahi G, Rezaazadeh H, Pourshanazari AA, Effect of co-administration of morphine and nicotine on cardiovascular function in two-kidney one clip hypertensive (2K1C) rats, Bosn. J. Basic Med. Sci 13 (2013) 140–145, 10.17305/bjbsms.2013.2345. [PubMed: 23988163]

[175]. Bądzyńska B, Lipkowski AW, Olszyński KH, Sadowski J, Different blood pressure responses to opioids in 3 rat hypertension models: role of the baseline status of sympathetic and renin-angiotensin systems, Can. J. Physiol. Pharmaco 94 (2016) 1159–1169, 10.1139/cjpp-2016-0111.

[176]. Parra L, Pérez-Vizcaíno F, Alassa A, Martín ML, Tamargo J, mu- and delta-opioid receptor-mediated contractile effects on rat aortic vascular smooth muscle, Eur. J. Pharmaco 277 (1995) 99–105, 10.1016/0014-2999(95)00067-u.

[177]. Parekh N, Dobrowolski L, Zou AP, Steinhause M, Nitric oxide modulates angiotensin II- and norepinephrine-dependent vasoconstriction in rat kidney, Am. J. Physiol 270 (1996) R630–R635, 10.1152/ajpregu.1996.270.3.R630. [PubMed: 8780230]

[178]. de Wit C, Bolz SS, Kaas J, Pohl U, Myogenic effects enhance norepinephrine constriction: inhibition by nitric oxide and felodipine, Kidney Int. Suppl 67 (1998) S122–S126, 10.1046/j.1523-1755.1998.06723.x.

[179]. Kolo LL, Westfall TC, Macarthur H, Nitric oxide decreases the biological activity of norepinephrine resulting in altered vascular tone in the rat mesenteric arterial bed, Am. J. Physiol. Heart Circ. Pharmaco 286 (2004) H296–H303, 10.1152/ajpheart.00668.2003. [PubMed: 14684362]

[180]. Barszczewska B, Jaroszewski JJ, The influence of nitric oxide on the contractile activity of the isolated porcine ovarian and uterine arteries, Pol. J. Vet. Sci 7 (2004) 83–90. [PubMed: 15230537]
[181]. Cunha TM, Roman-Campos D, Lotufo CM, Duarte HL, Souza GR, Verri WA Jr, Funez MI, Dias QM, Schivo IR, Domingues AC, Sachs D, Chiavegatto S, Teixeira MM, Hothersall JS, Cruz JS, Cunha FQ, Ferreira SH, Morphine peripheral analgesia depends on activation of the PI3Kγ/AKT/nNOS/NO/KATP signaling pathway, Proc. Natl. Acad. Sci. USA 107 (2010) 4442–4447, 10.1073/pnas.0914733107. [PubMed: 20147620]

[182]. Hashemi M, Karami M, Zarrindast MR, Role of nitric oxide in the rat hippocampal CA1 in morphine antinociception, Brain Res. 1313 (2010) 79–88, 10.1016/j.brainres.2009.11.020. [PubMed: 19931515]

[183]. Numajiri N, Takasawa K, Ohno K, Hayakawa W, Asada M, Matsuha A, Azumi K, Kamata H, Nakamura T, Minami M, Lipton SA, Uehara T, On-off system for PI3-kinase-Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN), Proc. Natl. Acad. Sci. USA 108 (2011) 10349–10354, 10.1073/pnas.1103503108. [PubMed: 21646525]

[184]. Kemp-Harper BK, Velagic A, Paolocci N, Horowitz JD, Ritchie RH, Cardiovascular therapeutic potential of the redox siblings, nitric oxide (NO) and nitroxyl (HNO), in the setting of reactive oxygen species dysregulation, Handb. Exp. Pharm 264 (2021) 311–337, 10.1007/164_2020_389.

[185]. Nardi GM, Bet AC, Sordi R, Fernandes D, Assreuy J, Opioid analgesics in experimental sepsis: effects on physiological, biochemical, and haemodynamic parameters, Fundam. Clin. Pharm 27 (2013) 347–353, 10.1111/j.1472-8206.2012.01041.x.

[186]. Jeger V, Arrigo M, Hildenbrand FF, Müller D, Jirkof P, Seifert B, Arras M, Spahn DR, Bettex D, Rudiger A, Improving animal welfare using continuous nalbuphine infusion in a long-term rat model of sepsis, Intensive Care Med. Exp 5 (2017) 23, 10.1186/s40635-017-0137-2. [PubMed: 28429311]

[187]. Liu L, Yan Y, Zeng M, Zhang J, Hanes MA, McMahon TJ, Dickfeld T, Marshall HE, Que LG, Stamler JS, Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock, Cell 116 (2004) 617–628, 10.1016/s0092-8674(04)00131-x. [PubMed: 14980227]

[188]. Hosseini M, Taiarani Z, Hadjzadeh MA, Salehhabadi S, Taheri SA, Aghaie HA, Different responses of nitric oxide synthase inhibition on morphine-induced antinociception in male and female rats, Pathophysiology 18 (2011) 143–149, 10.1016/j.pathophys.2010.05.004. [PubMed: 20558049]

[189]. Seckler JM, Meyer NM, Burton ST, Bates JN, Gaston B, Lewis SJ, Detection of trace concentrations of S-nitrosothiols by means of a capacitive sensor, PLoS One 12 (2017), e0187149, 10.1371/journal.pone.0187149. [PubMed: 29073241]

[190]. Lang RJ, Watson MJ, Effects of nitric oxide donors, S-nitroso-L-cysteine and sodium nitroprusside, on the whole-cell and single channel currents in single myocytes of the guinea-pig proximal colon, Br. J. Pharm 123 (1998) 505–517, 10.1038/sj.bjp.0701605.

[191]. Lang RJ, Harvey JR, Mulholland EL, Sodium (2-sulfonatoethyl) methanethiosulfonate prevents S-nitroso-L-cysteine activation of Ca2+-activated K+ (BKCa) channels in myocytes of the guinea-pig taenia caeca, Br. J. Pharm 139 (2003) 1153–1163, 10.1038/sj.bjp.0705349.

[192]. Xia Y, Haddad GG, Ontogeny and distribution of opioid receptors in the rat brainstem, Brain Res. 549 (1991) 181–193, 10.1016/0006-8993(91)90457-7. [PubMed: 16530811]

[193]. Arvidsson U, Riedl M, Chakrabarti S, Lee JH, Nakano AH, Dado RJ, Loh HH, Law PY, Wessendorf MW, Elde R, Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord, J. Neurosci 15 (1995) 3328–3341, 10.1523/JNEUROSCI.15-05-03328.1995. [PubMed: 7751913]

[194]. Arvidsson U, Dado RJ, Riedl M, Lee JH, Law PY, Loh HH, Elde R, Wessendorf MW, delta-Opioid receptor immunoreactivity: distribution in brainstem and spinal cord, and relationship to biogenic amines and enkephalin, J. Neurosci 15 (1995) 1215–1235, 10.1523/JNEUROSCI.15-02-01215.1995. [PubMed: 7532700]

[195]. Arvidsson U, Riedl M, Chakrabarti S, Vulchanova L, Lee JH, Nakano AH, Lin X, Loh HH, Law PY, Wessendorf MW, Elde R, The kappa-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids, Proc. Natl. Acad. Sci. USA 92 (1995) 5062–5066, 10.1073/pnas.92.11.5062. [PubMed: 7539141]
[196]. Ding YQ, Kaneko T, Nomura S, Mizuno N, Immunohistochemical localization of mu-opioid receptors in the central nervous system of the rat, J. Comp. Neurol 367 (1996) 375–402, 10.1002/(SICI)1096-9861(19960408)367:3<375::AID-CNE5>3.0.CO;2-2. [PubMed: 8698899]

[197]. Laferrière A, Liu JK, Moss IR, Mu- and delta-opioid receptor densities in respiratory-related brainstem regions of neonatal swine, Brain Res. Dev. Brain Res 112 (1999) 1–9, 10.1016/s0165-3806(98)00149-7. [PubMed: 9974154]

[198]. Hedner T, Cassuto J, Opioids and opioid receptors in peripheral tissues, Scand. J. Gastroenterol. Suppl 130 (1987) S27–S46, 10.3109/00365528709090997.

[199]. DiCello JJ, Carbone SE, Saito A, Rajasekhar P, Ceredig RA, Pham V, Valant C, Christopoulos A, Veldhuis NA, Canals M, Massotte D, Poole DP, Mu and delta opioid receptors are coexpressed and functionally interact in the enteric nervous system of the mouse colon, Cell. Mol. Gastroenterol. Hepatol 9 (2020) 465–483, 10.1016/j.jcmgh.2019.11.006. [PubMed: 31759144]

[200]. Babalonis S, Walsh SL, Therapeutic potential of opioid/cannabinoid combinations in humans: review of the evidence, Eur. Neuropsychopharmacol 36 (2020) 206–216, 10.1016/j.euroneuro.2020.03.002.

[201]. Belvisi MG, Hele DJ, Cough sensors. III. Opioid and cannabinoid receptors on vagal sensory nerves, Handb. Exp. Pharm 187 (2009) 63–76, 10.1007/978-3-540-79842-2_4.
(Panel A) Frequency of breathing, (Panel B) tidal volume, (Panel C) minute ventilation and (Panel D) mean arterial blood pressure (MAP) values before (Pre), and during the continuous infusion (I5 min onward) of vehicle (VEH, 20 μL/min, IV) or S-nitroso-L-cysteine (SNO-L-CYS, 1 μmol/kg/min, IV), or S-nitroso-D-cysteine (SNO-D-CYS, 1 μmol/kg/min, IV) and upon bolus injection of morphine (2 mg/kg, IV; M5 onward) in isoflurane-anesthetized rats. There were 9 rats in each group. Data are presented as mean ± SEM. *P < 0.05, I15, I15 and I25 versus Pre and M5, M15, M25 versus I25. †P < 0.05, SNO-L-CYS or SNO-D-CYS versus vehicle. Repeated measures ANOVA statistics: Frequency of breathing, F_{2,24} = 11.11, P = 0.004, F_{24,144} = 10.21, P < 0.0001; Tidal volume, F_{2,24} = 36.01, P < 0.0001, F_{24,144} = 10.62, P < 0.0001; Minute Ventilation, F_{2,24} = 36.69, P < 0.0001, F_{24,144} = 13.40, P < 0.0001; Mean arterial blood pressure, F_{2,24} = 8.96, P = 0.0012, F_{24,144} = 6.70, P < 0.0001.
Fig. 2.
Arithmetic changes in (Panel A) frequency of breathing ($f_R$), (Panel B) tidal volume ($V_T$), (Panel C) minute ventilation ($V_E$) and (Panel D) mean arterial blood pressure (MAP) elicited by bolus injection of morphine (2 mg/kg, IV) in rats undergoing continuous infusions of vehicle (VEH, 20 μL/min, IV), S-nitroso-L-cysteine (L-CSNO, μmol/kg/min, IV) or S-nitroso-D-cysteine (D-CSNO, 1 μmol/kg/min, IV) in isoflurane-anesthetized rats. There were 9 rats in each group. Data are presented as mean ± SEM. *P < 0.05, significant change from Pre. †P < 0.05, L-CSNO versus vehicle or D-CSNO. Repeated measures ANOVA statistics: Frequency of breathing, $F_{2,24} = 45.26$, P < 0.0001, $F_{24,144} = 5.66$, P < 0.0001; Tidal volume, $F_{2,24} = 43.30$, P < 0.0001, $F_{24,144} = 10.75$, P < 0.0001; Minute Ventilation, $F_{2,24} = 96.24$, P < 0.0001, $F_{24,144} = 5.55$, P < 0.0001; Mean arterial blood pressure, $F_{2,24} = 9.61$, P = 0.0009, $F_{24,144} = 7.24$, P < 0.0001.
Fig. 3. (Panels A–D) Arterial blood-gas chemistry (pH, pCO$_2$, pO$_2$, maximal sO$_2$) and (Panel E) Alveolar-arterial (A-a) gradient values before (Pre), and during the continuous infusion (15 min onward) of vehicle (VEH, 20 μL/min, IV) or S-nitroso-L-cysteine (SNO-L-CYS, 1 μmol/kg/min, IV) or L-cysteine (1 μmol/kg/min, IV), and upon the bolus injection of morphine (2 mg/kg, IV; M5 onward) in isoflurane-anesthetized rats. There were 5 rats in each group. Data are presented as mean ± SEM. *P < 0.05, I15, I15 and I25 versus Pre and M5, M15, M25 versus I25. †P < 0.05, SNO-L-CYS or SNO-D-CYS versus vehicle. Repeated measures ANOVA statistics: pH, $F_{2,24} = 3.86$, $P = 0.051$, $F_{12,84} = 4.95$, $P < 0.0001$; pCO$_2$, $F_{2,12} = 35.27$, $P < 0.0001$, $F_{12,72} = 5.07$, $P < 0.0001$; pO$_2$, $F_{2,12} = 43.13$, $P < 0.0001$, $F_{12,72} = 5.74$, $P < 0.0001$; Maximal sO$_2$, $F_{2,12} = 12.80$, $P = 0.0011$, $F_{12,72} = 8.82$, $P < 0.0001$. A-a gradient, $F_{2,12} = 20.96$, $P = 0.0001$, $F_{12,72} = 5.67$, $P < 0.0001$.
Fig. 4.  
(Panel A–D) Arterial blood-gas chemistry (pH, pCO\textsubscript{2}, pO\textsubscript{2}, maximal sO\textsubscript{2}) and (Panel E) Alveolar-arterial (A-a) gradient values before (Pre), and during the continuous infusion (I15 min onward) of vehicle (VEH, 20 μL/min, IV) or S-nitroso-D-cysteine (SNO-D-CYS, 1 μmol/kg/min, IV), and upon the bolus injection of morphine (2 mg/kg, IV; M5 onward) in isoflurane-anesthetized rats. There were 6 rats in each group. Data are presented as mean ± SEM. *P < 0.05, I15, I15 and I25 versus Pre and M5, M15, M25 versus I25. †P < 0.05, SNO-L-CYS or SNO-D-CYS versus vehicle. Repeated measures ANOVA statistics: pH, F\textsubscript{1,8} = 0.36, P = 0.56, F\textsubscript{8,48} = 20.93, P < 0.0001; pCO\textsubscript{2}, F\textsubscript{1,8} = 0.02, P = 0.90, F\textsubscript{8,48} = 6.69, P < 0.0001; pO\textsubscript{2}, F\textsubscript{1,8} = 0.01, P = 0.91, F\textsubscript{8,48} = 10.08, P < 0.0001; Maximal sO\textsubscript{2}, F\textsubscript{2,12} = 0.04, P = 0.85, F\textsubscript{8,48} = 6.92, P < 0.0001. A-a gradient, F\textsubscript{1,8} = 0.29, P = 0.60, F\textsubscript{8,48} = 4.33, P = 0.0006.
Fig. 5.
Arithmetic changes in (Panels A–D) arterial blood-gas chemistry (pH, pCO$_2$, pO$_2$ and maximal sO$_2$) values and (Panel E) A-a gradient elicited by injection of morphine (2 mg/kg, IV) in rats receiving continuous infusions of vehicle (VEH, 20 μL/min, IV), S-nitroso-L-cysteine (L-CSNO, μmol/kg/min, IV) or S-nitroso-D-cysteine (D-CSNO, 1 μmol/kg/min, IV) in isoflurane-anesthetized rats. There were 6 rats in each group. Data are presented as mean ± SEM. *P < 0.05, significant change from Pre. †P < 0.05, L-CSNO versus vehicle or D-CSNO. Repeated measures ANOVA statistics: pH, $F_{4,20} = 4.21$, $P = 0.01$, $F_{20,100} = 9.88$, $P < 0.0001$; pCO$_2$, $F_{4,20} = 18.59$, $P < 0.0001$, $F_{20,100} = 8.05$, $P < 0.0001$; pO$_2$, $F_{4,20} = 51.14$, $P < 0.0001$, $F_{20,100} = 4.33$, $P < 0.0001$; Maximal sO$_2$, $F_{4,20} = 10.22$, $P = 0.0001$, $F_{20,100} = 6.99$, $P < 0.0001$; A-a gradient, $F_{4,20} = 15.76$, $P < 0.0001$, $F_{20,100} = 4.84$, $P < 0.0001$. 

Biomed Pharmacother. Author manuscript; available in PMC 2022 September 11.
Fig. 6.
Changes in tail-flick (TF) latency elicited by the continuous infusion (I5 min onward) of (Panel A) vehicle (VEH, 20 μL/min, IV) or S-nitroso-L-cysteine (SNO-L-CYS, 1 μmol/kg/min, IV) or L-cysteine (1 μmol/kg/min, IV) or (Panel B) vehicle (VEH, 20 μL/min, IV) or S-nitroso-D-cysteine (SNO-D-CYS, 1 μmol/kg/min, IV), and bolus injection of morphine (2 mg/kg, IV; M5 onward) in isoflurane-anesthetized rats. There were 9 rats in each group except for the L-cysteine group, which had 6 rats. Data are presented as mean ± SEM.

*P < 0.05, I15, I15 and I25 versus Pre and M5, M15, M25 versus I25. †P < 0.05, SNO-L-CYS versus vehicle. (Panel C) Arithmetic changes in TF latency elicited by injection of morphine (2 mg/kg, IV) in rats undergoing continuous infusions of vehicle (VEH, 20 μL/min, IV), S-nitroso-L-cysteine (L-CSNO, μmol/kg/min, IV) or S-nitroso-D-cysteine (D-CSNO, 1 μmol/kg/min, IV) in isoflurane-anesthetized rats. There were 9 rats in each group. Data are presented as mean ± SEM. *P < 0.05, significant change from Pre. †P < 0.05, L-CSNO versus vehicle or D-CSNO. Repeated measures ANOVA statistics for SNO-L-CYS study (Panel A): F_{2,21} = 64.60, P < 0.0001, F_{21,126} = 2.03, P = 0.0088. Repeated measures ANOVA statistics for SNO-D-CYS study (Panel B), F_{1,16} = 2.70, P = 0.12, F_{16,96} = 3.105, P = 0.0003. Repeated measures ANOVA statistics for arithmetic changes in TF latencies (including the L-Cysteine group not shown in panels) (Panel C): F_{4,37} = 31.44, P < 0.0001, F_{37,185} = 3.27, P < 0.0001.